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CHAPTER ONE 
OBJECTIVES 
1. To document the Groote Schuur Hospital experience of the incidence, clinical and labora-
tory features, associated systemic disorders and response to therapeutic regimens in pa-
tients with pyoderma gangrenosum seen at Groote Schuur Hospital between 1970 and 1990. 
2. To compare the Groote Schuur experience with other reported series based on a lit-
erature review. 
3. To formulate an appropriate protocol for the diagnostic evaluation and treatment of the · 
patient presenting with pyoderma gangrenosum. 
2 
CHAPTER TWO 
LITERATURE REVIEW 
INTRODUCTION 
The original article by Brunsting et al,1 established pyoderma gangrenosum (PG) as a dis-
tinct clinical entity characterized by exacerbation and remissions of morphologically unique 
cutaneous ulcers. Although bacteria are not the cause, and gangrene almost never super-
venes, the term Pyoderma Gangrenosum remains well entrenched in the medical literature. 
PG is frequently thought to be a manifestation of an underlying systemic disease. In Brun-
sting's series of 19301, four of the patients sufferred from ulcerative colitis and one had a 
chronic empyema. Subsequent reports2•3•4 emphasised the association with, bowel disease al-
though the list of a wide variety of other systemic diseases continues to grow. It has become 
increasingly apparent that PG is not limited to one systemic disease setting5. 
In 20% to 30% of patients with PG, no associated disease process can be identified at the 
time the cutaneous lesions first appear2•3•4. The diagnosis of PG still depends principally on 
the medical history and the clinical examination of the patient focussing specifically on the 
appearance of the cutaneous lesions and exclusion of other various disease processes6. No 
specific laboratory or histologic feature of this disease has been demonstrated. In fact, a 
diversity of associated disorders and laboratory abnormalities found in patients with PG has 
done little to elucidate its pathogenesis, and treatment remains empiric. 
CLINICAL FEATURES 
Little can be done to improve on the original description by Brunsting et al1 of the skin le-
swns: 
"The borders of the ulcer were well defined because of their striking blue col01; which clearly out-
lined the lesion as it e.x:tended peripherally in rough se1piginous configuration. The blue zone con-
sisted of an edematous, boggy strip from 5 to Smm wide, in which there had been e.;'Ctensive 
undermining and necrosis of the subcutaneous tissue, the epidermis remaining as a thin, gray, 
translucent film extending over tile crater of L.' .. e l ;ston, in a ragg<Jd, iJTegularfashion (figure 1). 
Healing occurred by epithelial outgrowths from the periphe1y with resultant thin, atrophic scarring, 
with some brownish pigmentation (figure 2). The elementmy lesions occurred in crops as small, 
discrete pustules surrounded by an injlammat01y areola. Within a few days, the center of the pus-
tule softened and the covering skin became blue and broke down (figure 3). The lesion either 
unde1went involution or extended peripherally, to coalesce with others adjoining to fonn a large1; 
superficial ulcerative process, as described. " 
Figure 1 : "Classic" PG (case 4) 
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Figure 2 : Atrophic scarring and brown pigmentation of healed PG (case 27) 
Figure 3 : Vesico-pustules and developing ulcers of early PG (case 27) 
The lesions may appear anywhere on the body, including the mucous membranes, but are 
found most commonly on the legs 7. They may be single or multiple, developing simulta-
5 
neously or in sequence. Pain is a prominent feature and is sometimes so severe that narcotic 
analgesia is required. Local trauma or irritation is thought to incite some of the early le-
sions. In Perry's series3, 18 of the 62 patients with PG (25,8 percent) gave a history of 
preceding trauma at the site at which the PG developed. A similar percentage of patients in 
the largest series to date4, 23 of 86 (26,7 percent) patients, gave a history of a precipating 
factor that varied from minor trauma to surgical procedures. Other reports emphasize the 
. . f . . h d l f PGS-lO assoctatwn o mmor trauma or surgery m t . e eve opment o . 
Pyoderma gangrenosum may affect patients in any age group. It has been described in pa-
tients from the first decade 11,12 to the ninth decades of life13'14. However, most of the pa-
tients reported, developed their PG between 25 and 45 years of age4. 
The natural history of this disorder follows one of two patterns15,16: 
( 1) ACUTE, RAPIDLY PROGRESSIVE, in which the u leers enlarge dramatically during a 
period of days, unless arrested by systemic treatment. 
(2) CHRONIC, SLOWLY PROGRESSIVE, where the ulcers slowly enlarge during a peri-
od of weeks to months. Systemic therapy is not always indicated if adequate facilities are 
available for good local therapy. 
CLINICAL VARIANTS OF PG 
MALIGNANT PYODERMA OR PYODERMA GANGRENOSUM OF HEAD AND NECK 
The clinical entity of malignant pyoderma (MP) was first described by Perry et al in 196817, 
who regarded it as distinct from the accepted description of pyoderma gangrenosum, for 
the following reasons : 
(a) The atypical location of the lesions (predominantly on the head and neck) 
(b) The absence of undermined borders and erythema around the ulcers (figure 4). 
Figure 4: Atypical PG of head and neck (case 5) 
6 
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However, since that publication, subsequent reports18•19 have challenged the supposition 
that MP or PG of the head and neck (except for its site) is different from pyoderma gan-
grenosum elsewhere on the body. As far back as 1931, a 28 year old woman with known 
chronic ulcerative colitis was described as having severe pustular and ulcerative lesions con-
fined to the face and neck and a diagnosis of pyoderma gangrenosum was made20• 
Further reports21-24 support the contention that PG and MP are probably identical disor-
ders since many of the lesions, despite the location on head or neck, had the typical blue 
undermined border of classic PG, were often associated with an underlying disorder andre-
sponded !ike Perry's "malignant pyodermas" to systemic corticosteroids. Most dermatolog-
ists also believe that the term malignant to describe this form of pyoderma is 
inappropriate18. 
BULLOUS PG ORA 1YPICAL PG 
This variant was first described by Perry and Winkelmann in 197225. They reported 3 pa-
tients who developed unusual skin lesions that were suggestive of pyoderma gangrenosum 
but were more superficial, less destructive of tissue and had concentric bullous inflamma-
tory areas of involvement spreading centrifugally throughout the lesions. The borders of the 
lesions had a more subdued blue-gray appearance as opposed to the striking deeply purple 
colour of the more typical PG lesions. All 3 patients, on investigation were found 'to be suf-
fering from leukaemia. They concluded that the skin lesions were an atypical form of PG by 
excluding leukaemic infiltrates and known causes of pyodermatous skin lesions. 
Since this report, the association of atypical PG with leukaemia and pre-leukaemic condi-
tions has been well established26-32. The course of the skin lesions may, but does not always, 
parallel the course of the underlying disease. Healing occurs with a more superficial scar 
than is seen in typical PG. 
ORAL PYODERMA GANGRENOSUM 
8 
Reports of PG involving the oral cavity are rare. Basu et al33 reported 2 out of 100 patients 
with inflammatory bowel disease (IBD) who had oral mucosal lesions analagous to PG. 
These lesions were described as irregular shaped ulcers, 15 to 20mm diameter, with rolled 
out margins and a greyish-coloured base. The ulcers were painful and developed over a peri-
od of four to eight weeks during a stage when bowel symptoms were present and laboratory· 
tests suggested considerable activity. The majority of the reports of oral PG33-36, have been 
described in association with inflammatory bowel disease (IBD). There have been two pub-
lished reports of oral PG where evidence of underlying systemic disease was lacking37•38• In 
every case thus far, the oral lesions were accompanied by cutaneous ulcers. 
PYOSTOMA TITIS VEGETANS 
Pyostomatitis vegetans is a rare and unusual disorder of the oral cavity, characterized by ery-
thema and oedema of the mucosa, studded by numerous small superficial yellow pustules. 
Its significance lies in its association with IBD, either ulcerative colitis or Crohn's disease39. 
Callen 7 suggests that pyostomatitis vegetans is a potential variant of PG based on its strong 
association with IBD, repeatedly negative cultures of the oral abscesses and pustules for 
bacteria, viruses and fungi and associated ulcerative and vegetative skin lesions, which in 
some patients resembled classic pyoderma gangrenosum. Me Carthy, on the other hand, 
h f. . d h 0 • • 194939 d h 40-42 d w o 1rst come t e term pyostomatltis vegetans m an ot er reporters , regar 
this entity as a specific marker for inflammatory bowel disease, rather than oral PG. The le-
sions are uniformly responsive to systemic corticosteroids. 
PUSTULAR ERUPTION OF ULCERATIVE COLITIS 
Some authors regard this as a variant of pyoderma gangrenosum as some of the pustular le-
sions in this group of patients were seen to progress to more typical lesions of PG43-45. 
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O'Loughlin and Perry 44 were probably responsible for the first description of this entity. 
The initial lesions were multiple, small, 1 to 3mm pustules on an erythematous base, widely 
scattered over many surfaces on the body. They differed from pustular psoriasis in that they 
did not occur in sheets. Callen and Woo43 described a patient in whom hundreds of pus-
tules developed and yet only three resulted in typical ulceration of PG. The pustules were 
sterile when cultured. All of the reported patients with this variant had ulcerative colitis. 
Like classic PG, the course of the skin lesions did not necessarily parallel the course of the 
underlying disease 44. 
SUPERFICIAL GRANULOMATOUS PYODERMA: A LOCALIZED VEGETATIVE 
FORM OF PYODERMA GANGRENOSUM. 
Wilson-Jones and Winkelmann described this form of pyoderma gangrenosum in 198846. In 
this report, twenty five patients who presented with chronic superficial ulcerative pyoderma 
were considered clinically, by experienced clinicians, to be suffering from pyoderma gan-
grenosum. The characteristic indolent lesions with sinuses, vegetative or crusted borders, 
and cribriform scars were often single and recurrent. The back was the most common loca-
tion of the lesions (figure 5). The recurrence and spread of individual lesions with the ab-
sence of an infectious cause, suggested the diagnosis of pyoderma gangrenosum, as did the 
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presence of multiple lesions in a few cases. The superficial nature of the ulcers and the lack 
of liquefying, rapidly advancing borders were different from classic pyoderma gangrenosum. 
The histopathologic pattern in these cases were distinct and of a granulomatous nature with 
superficial, focal abscesses surrounded by histiocytes and foreign body giant cells. 
The lesions frequently healed without corticosteroid therapy or even spontaneously. Wilson-
Jones and Winkelmann believe that they have described a unique clinico-pathological en-
tity, which is perhaps a limited form of pyoderma gangrenosum, the recognition of which 
offers an opportunity for a conservative medical approach. (In their series of 25 patients, 
healing occurred without systemic corticosteroid treatment in all but 3 patients). Follow-up 
showed that the lesions healed within a short time after the initiation of consistent therapy. 
The majority of these patients (21 of 25) demonstrated no underlying systemic disease. 
Figure 5 : Localised, vegetative form of PG (case 40) 
UNUSUAL SITES FOR PYODERMA GANGRENOSUM 
Special mention is made of the following sites where pyoderma gangrenosum may not be 
readily recognized and thus be misdiagnosed. 
PARASTOMAL PYODERMA GANGRENOSUM 
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The occurrence of PG around the stomal sites was first brought to notice by Me Garity et al 
in 198447. They suggested that parastomal pyoderma gangrenosum may be under-reported 
because of a general unfamiliarity with this l~sion and the difficulty in distinguishing it from 
other parastomal skin lesions, such as parastomal dermatitis, fistulas from recurrent 
Crohn's disease, abscesses from suture reaction or wound contamination, pyogenic skin in-
fections, Meleney's ulcer, deep or intermittent mycotic infection, necrotizing vasculitis and. 
factitial ulcerations. In their cases, the parastomal PG showed wide variability in time of ap-
pearance relative to first surgery for Crohn's disease, disease course, response to medical 
therapy, and relationship to underlying disease. The optimal medical treatment of parasto-
mal pyoderma gangrenosum appeared to be corticosteroids combined with local wound 
care. If this regimen failed, revision and/or relocation of the ileostomy appeared to give 
good results. Parastomal PG may be commoner in patients with Crohn's disease than is 
generally believed48. 
GENITAL REGION 
Involvement of the genital region by pyoderma gangrenosum is rare. The appearance and 
course may in no way differ from pyoderma gangrenosum elsewhere on the cutaneous sur-
face, but special problems may arise with regard to perineal support, grafting and patient 
emotional response 49•50. In the reports referred to, both patients required extensive de-
bridement and grafting with adequate systemic corticosteroid cover before healing oc-
curred. Strong psychological and emotional support played a major role in management. 
PG of the penile and scrotal skin was the presenting feature of underlying inflammatory 
bowel disease in a patient reported by Sanusi et ai51. 
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Maule et al52 recommend that in patients with IBD and perianal ulceration, peri-anal PG 
should always be excluded. Hughes et al53, whose report on anal Crohn's disease prompted 
Maule's recommendation, agreed that similarities between peri-anal PG and the cavitating 
ulcers seen in Crohn's disease do exist, but that the latter were distinct from PG for the fol-
lowing reasons: first, the cavitating ulcers described in Crohn's disease were all at the level 
of the ano-rectal ring; second, the anal lesions tend to progress more slowly (in contrast to 
PG, which tends to be rapidly progressive); third, the ulcers in PG tend to respond to a 
short sharp course of high-dose oral steroid therapy, whereas in their experience, the cavi-
tating ulcers in anal Crohn's disease do not. Fourth, PG is a relatively uncommon complica-
tion of Crohn's disease occurring in only 0.8% of a series of 961 patients described by 
Schoetz et al54, whereas the cavitating ulcer is more common, and is one of the distinctive 
clinicopathological features of Crohn's disease. 
HISTOPATHOLOGY 
The histopathology of PG is not specific but is helpful in that the physician can rule out 
other disorders that may clinically appear as cutaneous ulceration 7. 
Suet al55 studied the largest group of patients with PG (63 biopsy specimens) and found 3 
patterns of histologic changes, depending on the site of biopsy: 
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(a) If the biopsy was obtained from the erythematous zone peripheral to the ulcer, the histo-
logic features were those of a lymphocytic vasculitis (endothelial swelling, fibrinoid ne-
crosis, thrombosis, extravasation of erythrocytes and predominanc_e of lymphocytes.) 
(b) If the necrotic, undermined edge of the ulcer was biopsied, a mixed cellular infiltrate of 
lymphocytes and neutrophils, lymphocytic vasculitis or perivascular inflammatory infiltra-
tion and early abscess formation were usually present. 
(c) If the specimen was taken from the ulcer floor, abscess formation and necrosis were ap-
parent (non-specific necrotic findings) 
They found that the level of involvement in the cutaneous biopsy specimens of pyoderma 
gangrenosum was usually deep. The majority showed involvement of panniculus as well as 
dermis (papillary and reticular). 
Although biopsy specimens taken from lesions of PG in the vast majority of patients lack 
the histologic appearance of necrotizing vasculitis2'13,56, a few exceptions have been de-
'b d57 58 59 Th 1 h d h h h. 1 . . . h . . sen e : ' . e atter aut ors suggeste t at t e Is to og1c picture m t e1r patients pro-
vided sufficient evidence for the vasculitic origin of PG. Callen maintains that -neither 
leucocytoclastic vasculitis nor granuloma formation is part of the picture of PG 7. 
The association of atypical bullous PG and Sweets syndrome (SS) with myeloproliferative 
disorders has been noted60. Both may be classified as neutrophilic dermatoses since they ex-
hibit intense dermal inflammatory infiltrates composed of neutrophils with no histologic evi-
dence of primary necrotizing vasculitis. There is obvious overlap between these two 
categories but the pathophysiologic mechanisms remain unknown. Some investigators have 
suggested that the inflammatory lesions of myeloproliferative disorders form a continuum . 
along a dynamic neutrophil-mediated proces's, ranging from classic SS to classic PG61•62. 
Lending further support that PG is a neutrophil mediated process is its development in le-
sions of subcorneal pustular dermatosis63. 
AETIOLOGY AND PATHOGENESIS 
14 
The causative mechanism of PG is unknown. Although there are a set of recognized sys-
temic disorders that are associated with PG, there has not been anything found in these con-
ditions that sheds light on the underlying mechanisms of disease formation 7. It is well 
established that infectious agents are not primarily involved. Repeated attempts at cultur-
ing early non-ulcerated lesions have failed to demonstrate viruses, fungi or bacteria. 
Although the exact mechanisms are uncertain, there is a belief that development of PG is 
related to a defective immune system13•64•65. Lazarus et al described four patients with cuta-
neous anergy and a lack of association between in vitro macrophage inhibition factor pro-
duction and antigen-induced incorporation of tritiated thymidine in cultured lymphocytes13. 
Failure of normal delayed response to DNCB, candida and streptokinase has also been 
demonstrated65. By this interpretation, lesions would occur when paralysis of the reticula 
endothelial system is unable to protect the tissues from the effect of minimal injury. New le-
sions can be provoked by skin pricks as in Behcet's syndrome, with which there is some 
overlap66. Such hyperactivity is greatest in the acute phase of the disease and near to exist-
ing lesions. 
It is possible that in some patients, a factor in serum inhibits in-vivo function of the lympho-
cyte. Lymphocytes from several patients with PG have failed to produce macrophage i'nhibi-
tory factor (MIF), and serum from one patient was unable to suppress the mixed lympho-
cyte reaction67. 
\ 
A serum dermonecrotic factor causing necrosis of guinea pig skin has been demonstrated 
but its specificity is doubtful65. 
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Tests of polymorphonuclear leucocyte function have demonstrated defects in phagocytosis 
chemotaxis, random migration and the ability to kill staphylococci68-70. 
The most compelling evidence of a defective immune mechanism lies in the increasing num-
ber of reports of PG associated with gammopathies 71, and other disorders of the reticulo-
endothelial system, such as T-cell imbalances 72. 
The role of immunoreactants in PG is unknown. Su et al noted deposits of IgG, IgA, IgM, 
C3 and fibrin in the papillary and reticular dermal vessels in 55 percent specimens studied, 
for which they had no valid explanation55. It was unlikely that they originated as circulating 
immune complexes in view of the multitude of reports failing to demonstrate circulating im-
mune complexes 7. 
A wide range of serological and biochemical tests have failed to reveal any significant or 
consistent abnormalities which may give insight into the pathogenesis of this unusual disor-
der73. 
Callen proposes that patients with PG have at least a partial defect in cell mediated im-
munity with an accompanying disturbance of polymorphonuclear leucocyte function and in 
such a predisposed individual, an inciting event, such as minor trauma, results in an abnor-
mal response, manifested as the clinical lesion of PG 7. 
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ASSOCIATED DISEASES 
PG has been reported with a wide range of inflammatory, neoplastic and auto-immune dis-
orders (Table 1) 7. 
TABLE 1: DISEASES ASSOCIATED WITH PYODERMA GANGRENOSUM 
Common Associations 
Jnflammatmy bowel disease (JED) 
Chronic ulcerative colitis (CUC) 
Regional enteritis, granulomatous colitis (Crohn's disease) 
Rheumatic diseases 
Seronegative with IBD 
Seronegative without IBD 
Rheumatoid arthritis 
Spondylitis 
Osteoarthritis 
Hematologic diseases 
Myelocytic leukemias 
Hairy cell leukemia 
Myelofibrosis, agnogenic myeloid metaplasia 
Monoclonal gammopathy (IgA) 
Rarely Reported Associations 
Chronic active hepatitis 
Myeloma 
Polycythemia ntbra vera 
Paroxysmalnoctumallzemoglobinwia 
Takayasu 's aneritis 
Primmy biliary cin-hosis 
Systemic lupus e1ytlzematosus 
Wegener's granulomatosis 
Hidradenitis suppurativa 
Acne conglobata 
Malignancy 
Thyroid disease 
Pulmonary disease 
Sarcoidosis 
Diabetes mellitus 
Other pustular dennatosis 
Endomet1iosis 
Belzcet's 
AIDS 
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Inflammatory bowel disease still appears to be the most frequently reported associ-
. 2 3 4 74 75 . B . 1 d h . . h 4 f h 5 . h d 1 atwn ,. ' ' ' smce runstmg et a reporte t e1r senes w ere o t e patients a u cer-
ative colitis3. However, Hickman and Lazarus in a reappraisal found that this association 
was not as common as formerly suggested 76. The other common associations are arthritis, 
haematologic diseases and paraproteinaemias (particularly lgA). 
ULCE;RA TJVE COLITIS 
The incidence of chronic ulcerative colitis (CUC) with PG has varied from 13 percent (2 of 
15 patients) reported by Holt et al 15, to 50 percent (31 of 62 patients) in a series reported 
by Perry3. In the latter study, 25 patients had the colitis prior to the onset of the skin le-
sions; in 2, the bowel and skin disease began at the same time, and in the remaining 4, the 
CUC was discovered as a result of evaluation of the skin. In a study of patients with PG and 
CU C from Cleveland Clinic 75 only 3 of 21 patients ( 14 percent) presented with PG prior to 
the recognition of ulcerative colitis. The majority of patients had active CUC at the time of 
d . . 75 IagnOSlS . 
Several authors have suggested that PG occurs in patients with severe attacks of colitis 77 
while others found no relationship between severity and extent of cue and the appearance 
ofPG75. 
The true frequency of CUC in patients with PG is probably around 10 percent, and the rela-
tionship of the activity of the skin disease to activity of the bowel disease is not consistent7. 
The speculation that PG in CUC is a result of immunological reaction to bacterial and die-
tary antigens absorbed through damaged colonic mucosa remains unproven. 
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CROHN'S DISEASE 
The frequency of Crohn's disease (regional enteritis) with PG varies from series to series, 
but is·generally low. In Perry's group of 62 patients3, not a single patient had Crohn's dis-
ease, '.Yhile in the Mayo clinic experience 4, 14 of86 patients (16,3 percent) had Crohn's. In 
the most recent of published series, Prystowsky et al found 2 of 21 patients (9,5 percent), 
suffering from Crohn's 78. Not only is the frequency of Crohn's disease in patients with PG 
low, but in Crohn's patients, PG is rare. This conclusion was reached by Schoetz et al who 
studied a group of 961 patients with Crohn's disease and found PG in only 8 patients (0,8 
percent)54. 
The relationship of the activity of the bowel disease to the activity of the skin ·disease has 
not been well studied. In Schoetz's group, all 8 patients developed their PG during an active 
phase of the disease 54. In two, the PG developed coincidentally with the onset of bowel 
symptoms, while the remaining 6 developed their skin lesions on an average of 7.3 years 
after developing Crohn's disease. They found that the most important part of treating the 
PG was controlling the underlying disease (a combination of surgery, systemic corticoste-
roids and sulfasalazine were usually employed). On the other hand, radical surgery to eradi-
cate the bowel disease does not necessarily preclude the development of PG thereafter75. 
ARTHRiTIS 
Joint disease is a common occurrence in patients with PG. Holt et al found 8 of 15 patients 
with PG who had an associated polyarthritis56. His was the first study to take a careful look 
at the pattern of arthritis in PG and he found that 4 of the 8 had a progressive, erosive, sym-
metrical seronegative polyarthritis which appeared to be peculiar to PG. He felt that this 
form of arthritis was unlikely to be a manifestation of inflammatory bowel disease (IBD) 
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since three of the four patients showed no evidence of bowel disease. In addition, "coli tic" 
arthritis is described as a distinctive, acute, oligo-articular, asymmetrical intermittent in-
flammatory disease, usually affecting large joints, does not progress to joint destruction and 
whose activity is closely related to the activity of the underlying bowel disease 79. The fourth 
patient, although having ulcerative colitis, again manifested a polyarthritis, unlike coli tic 
arthritis i.e. it preceded the onset of bowel symptons, was never punctuated by acute epi-
sodes, was not related to exacerbations of colitis, and was associated with x-ray evidence of 
para-articular bone bridging seen more typically in other sero-negative spondyloarthropa-
thies. The course of the arthritis in these 4 patients was progressive with development of dis-
abling joint deformities and erosive destruction of joints despite treatment with 
penicillamine, corticosteroids and non-steroidal anti-inflammatory drugs. 
Of the remaining 4 patients, 2 had seropositive, erosive rheumatoid arthritis, 1 had serone-
gative polyarthritis with ulcerative proctitis and 1 had seronegative polyarthritis with chond-
rocalcinosis. 
Powell et al also found that arthritis was the most frequent associated disorder (32 of 86 pa-
tients) in his series 4. Of these, 13 had seronegative arthritis with IBD and 9 seronegative 
arthritis without IBD. Of the remaining patients, 4 had classic seropositive rheumatoid arth-
ritis, 3 had ankylosing spondylitis and 3 had osteoarthritis. 
In the case of classic rheumatoid arthritis, it is often unclear whether the more appropriate 
diagnosis might be rheumatoid vasculitic ulcers rather than PG but, more often than not, a 
1 l . }' . . f d k' b' 715 eucocytoc ashe vascu 1t1s IS not oun on s m wpsy ' . 
In those patients, with a seronegative rheumatoid-like arthritis that is not associated with in-
flammatory bowel disease, the arthritis seems to follow the same course as the PG 7. 
In Perry's series of 62 patients scant attention was paid to the presence or absence of arth-
ri tis3. 
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Although a few patients with PG exhibit seropositive rheumatoid arthritis80, the majority of 
patients show negative findings on serologic examination5. 
The relationship between arthritis and PG is difficult to sort out, particularly since inflam-
matory bowel disease and pyoderma gangrenosum each have their own arthritic compo-
nents6. 
HAEMATOLOGICAL MALIGNANCY 
An atypical form of PG (a superficial, bullous variety) is usually reported in association with 
leukaemia and pre-leukaemic syndromes25-32. However, the more typical PG ulcers have 
been reported as well26·81. Usually, the PG post-dates the development of the haematologi-
cal disorder, but may be the presenting sign82•83. 
Recurrence of skin lesions may herald a relapse of the leukaemia in a patient in re-
mission27. Most frequently, the leukaemia has been of the myelocytic series usually an 
acute myelomonocytic leukaemia 7, although the number of reports in association with the 
1 k · f 1 f. b · d 1 d 1 · · · · 29 84 ss 86 pre eu aemJc state o mye o 1 ros1s an mye o ysp asia IS mcreasmg ' ' ' . 
Treatment of the haematological disease may lead to remission of the skin lesions although 
the presence of PG usually indicates severe disease25·27. 
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MONOCLONAL GAMMOPATHY AND MYELOMA 
The reported incidence of monoclonal gammopathies associated with PG has varied be-
. . 
tween 10 and 20%4'56,78. Usually the gammopathy was IgA71'87. Only rarely does the pa-
tient with a benign monoclonal gammopathy and PG progress to develop myeloma 71. 
Several patients with multiple myeloma have also been reported88, but this occurrence is 
much less frequent than the association with benign monoclonal gainmopath/8. Although 
the importance of the association of paraproteinaemia with PG remains unclear, patients 
with a gammopathy should be followed carefully for the rare development of myeloma 71. 
INTERNAL MALIGNANCIES 
Other than the established association of PG and leukaemias, the association of internal ma-
lignancies and PG is rare. The isolated reports suggest that the malignancy and the PG w~re 
probably coincidental, except for one report, where resection of an adrenocortical carcino-
ma in a patient with PG and long-standing ulcerative colitis, led to the complete clearing of 
the previously troublesome PG89. 
LESS COMMON DISEASE ASSOCIA TJONS 
The list of uncommon disease associations with PG continues to grow (Table 1). The num-
bers of these miscellaneous disorders, however, are too small to draw any conclusions. The 
exception may be large vessel vasculitis (Takayasu's disease) where a third of Japanese pa-
tients with this disease are reported to have coexisting PG90. 
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Ch . . h .. 91 . I h 92 d 'd . 93 f ' rome active epat1t1s , systemic upus eryt ematosus an sarcm os1s are some o 
the rarer conditions linked to PG. More recently, human immunodeficiency virus infection 
and PG has been reported in two children94. 
DIFFERENTIAL DIAGNOSIS , 
An important part of the evaluation of a patient with PG is to rule out other causes of cuta-
neous ulceration. This is particularly important in those patients who fail to respond to what 
is considered adequate treatment for PG. 
The following should be excluded : , 
(1) Infectious diseases such as tuberculosis (Callen had a patient sent from another centre 
with a diagnosis of PG who was found to have tuberculosis) 7, deep fungal infections (sporo-
trichosis masquerading as pyoderma gangrenosum is reported)95, bacterial (a leg ulcer of 
the PG type was in fact a manifestation of tertiary cutaneous syphilis)96, viral infections, and 
in the setting of acquired immunodeficiency syndrome (AJDS)97, bizarre organisms. 
(2) Halogenodermas 
(3) Vasculitis (Wegener's granulomatosis presented as PG)98 
( 4) Venous or arterial insufficiency 
(5) Neoplasms (Histiocytosis X mimicking pyoderma gangrenosum is reported in an adult)99 
(6) Drug eruptions100 
(7) Factitial ulcerations. 
(8) Chronic granulomatous disease101. 
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PROGNOSIS 
This is most predictable in those patients in whom an identifiable disease is recognizable 
and amenable to treatment. But even here, the prognosis is that of the associated disease · 
and this may be unfavourable, especially if the reticulo-endothelial system is involved. How-
ever, with ulcerative colitis and Crohn's disease, control of the internal condition can be ex-
pected to resolve the skin problem, although there are always exceptions54•75•102•103. 
TREATMENT 
It is difficult to evaluate the treatment of a condition in which pathogenesis is unknown, the 
disease course unpredictable (with spontaneous remissions), and where disease activity may 
be related to an associated underlying disorder16. As a result of these factors, the thera-
peutic manoeuvres take on the form of an art in medicine. Recognition of underlying dis-
ease amenable to treatment is important. PG in patients with leukaemia, especially of the 
acute type, has improved or cleared completely after chemotherapl5•27. Similarly, patients 
with PG and CAH have experienced dramatic clearing of their skin lesions when the he-
patitis was treated with immunosuppressive agents91. In patients with CUC, skin lesions 
may respond to bowel resection, where oral therapy has failed 74. However, there are pa-
tients in whom total colectomy, including removal of the recto-sigmoid colon, failed tore-
sult in remission102, or where PG occurred years after bowel surger/03. It is, therefore, 
important to have the proper bowel indications for this aggressive approach. 
LOCAL THERAPY, regardless of the presence or absence of underlying associated dis-
ease, is important, since patients have been known to recover with topical treatment 
alone 4•46. In a disease characterized by pathergy, aggressive debridement should be 
avoided. Skin grafting should be avoided, if possible, but in cases of perineal involve-
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. . f 'd bl H b . . f k' . f . ment ' , It IS o ten unavm a e. yper anc oxygen preparation o s m pnor to gra tmg 
PG is recommended, as it is claimed to promote healing104. 
Other local measures include dressings,48 elevation, rest, topical agents like sodium cromog-
lycate105 and intralesional steroids106. 
Cleansing with antibacterial agents such as hydrogen peroxide or benzoyl peroxide have 
b d b b f . . 1 . . 1 . . 107 een reporte to e ene ICia m an occaswna patient . 
For those patients, not responding to local treatment, or in whom progression of the disease 
is dramatic and for patients with recurrent disease, systemic therapy is indicated. 
SULF ASALAZINE, in doses of 4g/day was the first widely and successfully used drug in 
the treatment of PG2. It had been used by gastroenterologists for treatment of ulcerative 
colitis, with good results, and, since pyoderma gangrenosum may parallel the course of intes-
tinal disease, it seemed reasonable to administer it for the treatment of the skin disease. It 
has been found to benefit patients with PG without IBD2. 
SULFAPYRIDINE, (which together with aminosalicylic acid is formed by the splitting of 
sulfasalzine by gut bacteria) has also been shown to be beneficial in those PG patients who 
have a dermatitis herpetiformis-like eruption2. In doses of up to 4glday, it proved an effec-
. 
4108 I h If l . d If 'd' . . tiVe treatment ' . t was apparent t at su asa azme an su apyn me were not actmg pn-
marily as antibacterial agents in pyoderma gangrenosum, since other antibiotics were 
usually ineffective, and maintenance therapy often used doses too low to induce optimal 
antimicrobial effects16. Since the spectrum of diseases responding to sulfapyridine therapy 
is similar to that responding to sulfone therapy, sulfones were also administered, (usually 
diaminodiphenylsulfone, in doses up to 400mg/day), and found to be beneficial in the treat-
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ment of pyoderma gangrenosum108. The anti-inflammatory effects of the sulfones may be 
related to their severe inhibition of the myeloperoxidase-H202-halide mediated cytotoxic 
system in polymorphonuclear leucocytes109 an accumulation of which characterizes PG le-
sions. Newell et al believe that sulfones are the drugs of choice in treatment of pyoderma 
gangrenosum, especially for the chronic, slowly progressive form of disease16. Treatment 
failures are thought to be the result of inadequate dosage. Disease resistant to sulfapyridine 
therapy may respond to sulfones and vice versa106. 
ADRENAL STEROIDS have been administered systemically for pyoderma gangrenosum 
for over 30 years110 and have become the most extensively used form of treatment. They 
are unquestionably effective and are considered by many to be the drug of choice for the 
acute, rapidly progressive form of the disorder56. Large oral doses of prednisone ( 40 to 
120mg/day) are usually required to arrest the disease. The successful use of pulse corticoste-
roid therapy in three patients with severe and/or recurrent disease111 and in combination 
with dapsone112 has been reported. The potential for cardiac arrythmias and death as are-
sult of electrolyte abnormalities mandates that pulse therapy be administered in a hospital 
setting with the appropriate monitoring. Pulse therapy refers to the use of suprapharmaco-
logic doses of corticosteroids (patients are infused with IG methylprednisolone in 150ml of 
5% dextrose between 8- 9am daily for three to five days). The pulse therapy is then fol-
lowed by maintenance therapy with oral prednisone combined with steroid sparing agents 
like sulfasalazine, dapsone or sulfapyridine 78. Prolonged maintenance therapy with oral 
adrenal steroids, even at relatively low dosage levels, may be associated with serious side ef-
fects. In one review, four patients died of what the authors termed "adrenal steroid - in-
duced complications"76. 
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CLOFAZAMINE, a phendimetrazine tartrate derivative previously used for its anti-micro-
bial effect against mycobacteria, has been found to be effective in the treatment of PG113-
115. The usual dose was 300mg/day. The mechanism of drug action is unknown. 
Clofazamine is known to enhance neutrophil phagocytosis and intracellular bacterial killing 
and stimulates macophage activity, but few of the patients treated had demonstrable defects 
in neutrophil or macrophage function 113•115. Other antimicrobial agents found to be suc-
cessful in some cases of PG are minocycline hydrochloride116-118 and rifampin26. Minocy-
cline may be effective in part because of the anti-inflammatory and anti chemotactic 
properties of the tetracycline, and presumably tetracycline derived drugs16. 
IMMUNOSUPPRESSIVE THERAPY is another less common but well described treat-
ment administered for systemic effects and is generally reserved for severe disease. Immu-
nosuppressive drugs have occasionally been used in combination with adrenal steroids, but 
in a small number of cases, these agents have been given as the sole form of treatment16. 
Azathioprine in dosages of 100 to 150mg/day, has been the most frequently used drug, and 
although it has not been universally beneficia! 56, it has been effective in patients with91•92 
and without associated underlying disease16. Cyclophosphamide has been rarely used but in 
one young patient with severe unresponsive PG, its use resulted in dramatic clearing of the 
skin lesions119. Encouraging responses were also obtained with the use of cyclosporin A in 
I . . h I . d 120-122 severa patients w1t reca Citrant pya erma gangrenosum . 
Other miscellaneous treatments used have included plasmapheresis123, and thalido-
mide65·124. Radiation therapy and electron beam irradiation have been attempted with little 
success125. Systemic antibiotics may be needed for troublesome secondary infection which 
is inevitably present in skin lesions of pyoderma gangrenosum. Treatment, although fre-
quently effective, remains' empiric. There is no single agent that is effective in all patients in 
whom it is used. Toxicity and undesirable side effects of the agents used are common. Fi-
nally, the need to be certain that the ulceration is not due to some other treatable cause, 
particularly infections, cannot be overstressed 7. 
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CHAPTER THREE 
MATERIALS AND METHODS 
The records of patients diagnosed as having pyoderma gangrenosum at Groote Schuur Hos-
pital, Cape Town, between 1970 and 1990 were obtained from the department of Informa.:. 
tics, Dermatology and Pathology at this institution and then reviewed (See Appendix). The 
patients' age at onset, the presence of precipitating factors, site of first lesion, duration of 
first course, recurrences, intervals of healing, therapy, response to treatment and follow-up 
periods were recorded. The histology reports and microscopic slides of those patients that 
were biopsied were obtained from the departments of Dermatology and Pathology. The his-
tology was reviewed with a consultant pathologist. Results of special tests, including serum 
protein electrophoresis and delayed hypersensitivity skin tests, were also reviewed. ln-
formed consent was obtained from those patients where identification was possible from 
photographs appearing in this publication. 
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CHAPTER FOUR 
RESULTS 
Pyoderma gangrenosum was diagnosed in 45 patients seen at Groote Schuur hospital be-
tween 1970 and 1990. In 41 patients, the diagnosis was made or confirmed by dermatolog-
ists in the department of dermatology, 2 (who had parastomal PG) were diagnosed by an 
experienced stoma therapy nursing sister, and 2 were diagnosed by physicians in the haema-
tology department. 
CLINICAL FEATURES 
In 41 patients (91.1 %), the diagnosis in the active phase was based on the clinical features 
of progressively enlarging ulcers with violaceous undermined borders, surrounded by a 
zone of erythema. 
Of the remaining 4, 2 (cases 33,34) were atypical PG of the head and neck (figures 6 and 7), 
1 (case 20) was the bullous variant of PG associated with a pre-leukaemic state (figure 8), 
while the fourth (figure 5, case 40) was classified as the localised vegetative variant de-
scribed by Wilson-Jones45. Oral involvement was documented in 4 patients (cases 1, 9, 26, 
39). 
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Figure 6: Atypical PG of head and neck (case 33) 
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igure 7: Atypical PG of head and neck in a child (case 34) 
Figure 8: Atypical bullous PG (case 20) 
igure 9: Age distribution of patients in GSH sedes 
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ln this study, 26 patients (57.8% ) were female and 19 ( 42.2% ) were male. The age of onset 
ranged from 8 to 72 years, with most patients developing their disease from the second 
through to the sixth decade (figure 9). Four patients (8.9% ) developed pyoderma gangreno-
sum in childhood, that is on or before the age of 14 years (cases 26, 34, 39, 41) _ 
The initial lesions of PG occurred at various sites (table 2). The lower limbs were the most 
frequently affected; 34 patients had lesions in this area, and 15 of the 34 had no other cuta-
neous involvement. Five patients (cases 2, 7, 8, 13, 14) had parastomal involvement (eg. 
figures 10 and 11), three, head and neck, two truncal, and one had the initial lesion invol-
ving the oral mucosa. 
if ABLE 2: SITE OF FIRST LESION 
LOWER LIMB: 
HEAD&NECK 
PARASTOMAL 
TRUNK 
ORAL MUCOSA 
igure 10: Parastomal PG (case 2) 
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Figure 11 : Parastomal PG (case 8) 
Three patients (cases 2, 10,28), in addition to lesions elsewhere, had severe perineal involve-
ment ( eg. Figure 12). 
~igure 12 : Perineal PG (case 2) 
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Pain in the lesions was a major feature in 35 patients. Twelve patients (28.6 percent) gave a 
history of a precipitating factor that varied from minor trauma to surgical procedures. 
Duration of first episode of PG varied from six weeks (case 31) to 18 years (case 33). In 22 
patients the course lasted between 1 and 5 years, in 16, it was less than 1 year and in there-
maining 7 patients it was longer than 5 years. 
Recurrences were documented in 5 patients (i.e. a recurrence being regarded as develop-
ment of PG at least 1 year after the previous episode and where patient had been off all 
therapy for PG, for the same period.) Intervals between recurrences varied from 16 months 
(cases 4, 22) to 12 years (case 15). The remaining two patients (cases 33 and 36) had periods 
of inactivity of approximately 2 years. Thirty-seven patients (from the clinical history avail-
able) could be regarded as the acute, rapidly progressive form of PG, while the remaining 8 
patients followed a more slowly progressive pattern. 
PRESENT STATUS (November 1990)(Figure 13) 
Ten patients had inactive disease off therapy, 10 were in remission on maintenance, 4 had 
active disease (3 on corticosteroid treatment, 1 on homeopathic medication), 13 are de-
ceased and the status at time of writing was unknown in 6. 
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Figure 1:3 :Status of patients in GSH series (November, 1990) 
INACTIVE(Off Rx) 
10 
DECEASED 
15 
DECEASED 
Cases 18-22, 25 
Cases 26,32, 39 
Cases 44,45 
Case 37 
Cases 23, 38, 43 
I NACTIVE(Malntnc) 
10 
ACTIVE 
4 
UNKNOWN 
6 
from underlying associated disease 
following complications as a direct result of cutaneous disease 
following complications of therapy for cutaneous disease 
due to unrelated causes 
unknown causes 
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AS SOCIA TED DISEASES 
Thirty-one patients had an associated disease (tables 3a & 3b). Of these, 13 had IBD, 6 had a 
haematological disorder, 4 were associated with rheumatoid arthritis, 3 had CAH and 1 
each suffered from Takaysu's arteritis, Behcet's syndrome, endometriosis, systemic vas-
culitis and an IgA gammopathy (figure 14).The associated disease preceded development of 
PG in 21 patients, coincided in 8 and occurred after a considerable period in the remaining 
2. 
If ABLE 3a: THE ASSOCIATION OF PG WITH SYSTEMIC DISEASES 
No Pat Sex Age and ;,ear of Associated Age and year of 
onset of G disease onset associated 
disease 
1 GS F 36 years (1975) Crohn's 43 years (1982) 
2U F- 26 years (1986) Crohn's, 15 years (1981) 
3MI F 26 years (1985) Crohn's 21 years (1980) 
4 MI F 41 years ( 1987) cue 41 years (1987) 
5 NS F 57 years (1989) cue 21 years (1989) 
6LN F 40 years (1989) Crohn's, Ankylosing 35 years (1984) 
spondylitis 36 years (1985) 
7RH F 55 years (1982) Crohn's 51 years ( 1980) 
sec F 30 years (1988) Crohn's, 22 years (1980) 
9AN M 37 years (1980) CAH 33 years (1976) 
cue 21 years (1965) 
lOAG M 20 years (1975) Crohn's 10 years (1965) 
11 PC F 43 years (1978) Crohn's 37 years (1972) 
12RN F 19 years ( 1980) Crohn's 17 years (1978) 
13EW F 31 years ( 1985) Crohn's 31 years ( 1985) 
14 GS F 51 years ( 1981) RA +ve 42 years (1972) 
TABLE 3b : THE ASSOCIATION OF PG WITH SYSTEMIC DISEASES 
No Pat Sex 
15 ss F 
16SA F 
17PM F 
18PH M 
19WJ M 
20MS F 
21 PS M 
22 ?? F 
23MB M 
24AV F 
25AB M 
26FB F 
27AL F 
28SP F 
29NB M 
30MM F 
31NM M 
Age and year of 
onset ofPG 
47 years (1975) 
41 years (1977) 
63 years (1984) 
59 years (1981) 
67 years (1987) 
72 years (1987) 
67 years (1985) 
19 years (1984) 
71 years (1971) 
18 years (1989) 
24 years (1973) 
11 years (1985) 
18 years (1984) 
45 years (1976) 
20 years (1975) 
17 years (1988) 
64 years (1990) 
Associated 
disease 
RA-ve 
RA-ve 
RA +ve 
AML 
Myelodysplasia 
Myelofibrosis 
Myelodysplasia 
AML 
AML 
CAH 
CAH 
CAH 
Takayasu's arteritis 
Endometriosis 
Behcet's syndrome 
Systemic vasculitis 
IgA gammopathy 
Abbreviations: CUC = Chronic ulcerative colitis 
Age and year of 
onset associated 
disease 
38 years (1966) 
21 years (1959) 
55 years (1976) 
59 years (1981) 
64 years (1984) 
59 years (1974) 
66 years (1984) 
19 years (1984) 
71 years (1971) 
13 years (1984) 
20 years (1969) 
8 years (1982) 
18 years (1984) 
43 years (1974) 
20 years (1975) 
17 years (1988) 
64 years (1990) 
RA + ve = Seropositive rheumatoid arthritis 
RA -ve = Seronegative rheumatoid arthritis 
AML = Acute myeloid leukaemia 
CAH = Chronic active hepatitis 
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'igure 14 :Associated diseases in 45 patients 
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IBD was the most common associated disease and was seen in 13 patients (28.8%) (cases 1-
13). Of these, 10 (76.9%) had Crohn's disease and 3 (23.1%) ulcerative colitis. Eightpa-
tients had active inflammatory bowel disease at the time their skin lesions developed. One 
asymptomatic patient demonstrated ulcerative colitis on radiographic examination. She had 
no bowel symptoms at the time she developed pyoderma gangrenosum and none had de-
veloped at follow-up 2 years later (case 4 ). One patient noted an exacerbation of her exist-
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ing pyoderma gangrenosum with a flare of the bowel activity (case 6). Three patients had in-
active bowel disease at the time of development of their skin lesions (cases 1, 2, 3 ). 
HAEMA TO LOGICAL DISORDERS 
Six patients had an associated haematological disorder (cases 18-23 ). Three had acute 
myeloid leukaemia (cases 17, 22, 23), 2 had myelodysplasia (cases 19, 21) and 1 (case 20) 
had myelofibrosis. All had active haematological disease at the time of diagnosis of PG. In 
one, the PG resolved when the underlying haematological malignancy was treated with cyto-
toxics. This same patient had a recurrence of pyoderma gangrenosum which coincided with 
an exacerbation of the acute myeloid leukaemia, during which flare she died. (This case was 
a subject of a previously published report29). One patient's pyoderma gangrenosum healed 
completely following pulse medrol therapy and never recurred despite deterioration of her 
myelofibrosis, from which she ultimately died (case 20, figure 8 ). One patient (case 21) died 
with a large recalcitrant lesion of his right thigh still present (figure 15) which failed tore-
spond to several modalities of treatment. His myelodysplasia, although stable, never ~om­
pletely remitted, and he eventually died from his underlying disease. The PG lesion 
remained virtually unchanged for a period of 2 years. 
Another patient who presented with pyoderma gangrenosum and was found to be suffering 
from acute myeloid leukaemia, died of overwhelming organ failure within 5 days of the diag-
nosis being made, despite the institution of cytotoxic therapy (case 18). The fifth patient de-
veloped PG approximately 3 years after a diagnosis of myelodysplasia was made, and the 
skin lesions resolved completely after oral prednisone therapy (case 19). He died of compli-
cations of the haematological disease 4 months after the skin lesions had healed. 
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'igure IS: PG associated with myelodysplasia (case 21) 
All six patients in this group are deceased. Three are known to have died with lesions of 
pyoderma gangrenosum present, two had none and the follow-up of the sixth patient is un-
known. 
ARTHRITIS 
Four patients (cases 14-17) had RHEUMATOID ARTHRITIS (2 seronegative, 2 seroposi-
tive). One (case 17) had active arthritis at the time she developed PG, while the remaining 
three were in remission on therapy. In the seronegative group, none demonstrated bowel 
symptomatology, although radiographic evidence of inflammatory bowel disease was not 
sought. One of these, (case 15) developed her PG at site of hip surgery (Figure 16). 
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-'igure 16 : PG occurring at site of surgery 
Three patients in the IBD group were documented as suffering from arthritis (cases 2, 6 and 
8). Cases 2 and 8 had arthritis of the "coli tic" type and radiographic evidence of erosive arth-
ritis was lacking. Patient 6 was found to be suffering from ankylosing spondylitis and had 
radiographic evidence to support this. Of the remaining patients in the GSH series, vague 
arthralgias were mentioned in some, but exact details were not available. 
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CHRONiC ACTIVE HEPATITIS (CAH) 
Four patients were documented as having an associated chronic active hepatitis (cases 9, 24-
26). Of these, case 9 had ulcerative colitis as well (and was included in the group with IBD). 
In this case, the CAH developed eleven years after a diagnosis of ulcerative colitis was 
·made. 
All 4 patients developed their cutaneous lesions between two and four years after CAH was 
diagnosed. 
Patient 25 has since died from his associated disease. Of the remaining three, case 9 had no 
recurrence of PG at follow~up 9 years later and the CAB was stable on treatmeJ?t; patient 
24 had no active lesions at time of writing (6 months after last flare of PG) and was stable 
on treatment, while case 26 continued to have active skin lesions at the time of writing and 
attempts at stabilizing the CAB were in progress (with initial indications of success.) 
OTHER DiSEASES 
Rare associations were present in 5 patients (cases 27-31). One each suffered from Behcet's 
syndrome, Takayasu's arteritis, endometriosis, systemic leucocytoclastic vasculitis, and one 
- . 
was found to have an incidental lgA gammopathy on serum protein and immunoelectro-
phoresis. In the first two patients, cutaneous lesions suggestive of PG were already present 
at the time the associated disease was diagnosed, but were only r~cognized as PG much 
later. Endometriosis was diagnosed in case 28 prior to the development of PG and case 30 
developed renal vasculitis several weeks after PG was diagnosed, while the patient with the 
IgA gammopathy (case 31) presented with a readily recognizable lesion of PG and no appar-
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ent underlying associated disorder, until immunoelectrophoresis revealed the IgA parapro-
tein. 
JDJOPATHIC PG (Table 4) 
In 14 patients with PG, no evidence of an underlying systemic disorder was found. Eleven 
were male. No pattern with regard to age, clinical presentation, course or prognosis 
emerged in this group when compared to the associated disease group except for the pre-
ponderance of females (21 of 31 patients, 67.7 percent) in the latter as opposed to the rela-
tively few females (3 of 14, 21.4 percent) in the idiopathic group. 
' TABLE 4: IDIOPATHIC PYODERMA GANGRENOSUM 
NO. PATIENT SEX AGE AT ONSET OF PG 
32 WL M 63 years (1971) 
33 PO M 16 years (1963) *1 
34 DF M 8 years (1985) 
35 RJ F 28 years (1989) 
36 PE M 11 years (1958) *2 
37 CB M 65 years (1976) 
38 MN F 34 years ( 1977) 
39 AM M 10 years (1978) 
40 MB M 34 years ( 1988) 
41 MA F 14 years (1972) 
42 NS M 46 years (1974) 
43 JT M 64 years (1969) *3 
44 TP M 42 years (1981) 
45 GT M 34 years ( 1978) 
*1,2,3: These paliellls were included in Lhis series as diagnosis of PG was made afier 1970, a/-
Lhough skin lesions were preselll for much longer (see case reporl.s). 
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LABORATORY INVESTIGATIONS 
The following investigations were done routinely in all patients at time of diagnosis (irre-
spective if an associated disease was known to be present or not): Full blood count, erythro-
cyte sedimentation rate (ESR), serum biochemistry, blood glucose, VDRL, Chest X-ray. 
In the idiopathic group, all of these investigations were normal or negative, except in 5 pa-
tients with extensive cutaneous disease, where the ESR was significantly raised (based on 
values for the GSH laboratories) (cases 38, 39, 43, 44, 45). These 5 patients also had evi-
dence of a normochromic, normocytic anaemia of chronic disorders. Two of these patients 
(cases 44, 45) had evidence of old pulmonary tuberculosis on chest X-ray at the time they 
developed PG (both subsequently developed active pulmonary tuberculosis while on corti-
costeroid therapy for their skin lesions). 
In the associated disease group, abnormalities in the routine investigations were usually ap-
propriate for the associated disease. The VDRL was negative in all patients in this group. 
Results of serum protein electrophoresis were available in 29 patients ( 12 were in the idio-
pathic group). 
No paraproteinaemias were present in the associated disease group (polyclonal, non-spe-
cific elevations were present in 7). 
ln the idiopathic group, only one patient (case 31) was found to have a benign lgA gammo-
pathy (urine was negative for Bence-Janes protein). In one other patient (case 34 ), with nor-
mal serum protein and immunoelectrophoresis, light chains of40 and 20 kappa were 
detected in the urine, but their significance was not determined (this patient completely re-
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covered after a short course of corticosteroid and dapsone therapy). Serum protein electro-
phoresis in the remaining 10 patients was either normal or showed a non-specific poly clonal 
elevation. Immunoelectrophoresis was not routinely requested in the GSH series. 
TESTS OF DELAYED HYPERSENSITIVITY 
(Mantoux or Candida intradermal test) 
Tests of delayed hypersensitivity were recorded in 12 patients. Strongly positive mantoux re-
actions were present in 4 patients, 3 of whom were found to have active pulmonary tubercu-
losis (patients 26, 44, 45). The fourth patient had an associated endometriosis but no 
evidence of active tuberculosis (case 28). Five patients were non-reactive to intradermal 
tuberculin, while the remainder were recorded as "normal". 
BOWEL STUDIES 
ASSOCIATED DISEASE GROUP (31 patients) 
Barium studies were undertaken in 7 patients in this group: 
Four of these patients had IBD and bowel studies were done at the time of development of 
PG: 
Case 1 - revealed long-standing Crohn's disease (this was diagnosed 8 years after onset of 
severe oral ulceration). 
Case 2 - a retrograde barium study through the ileostomy showed no evidence of recurrent 
Crohn's disease. 
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Case 4 - barium enema was done as part of the work-up for patients with "idiopathic" PG 
and revealed the radiological evidence of ulcerative colitis (the patient was clinically asymp-
tomatic). 
Case 5 - PG and bowel symptomatology occurred at almost the same time. Barium enema 
and rectal biopsy confirmed the presence of ulcerative colitis. 
The remaining 3 patients, cases 28-30, who had associated endometriosis, Behcet's syn-
drome and systemic vasculitis, respectively, all had normal gastro-intestinal tracts on screen-
mg. 
IDIOPATHIC GROUP (14 patients) 
Screening for IBD was undertaken in 13 patients of this group. Only 1 (case 4- who has 
now been included in the associated disease group) showed evidence of IBD, while the re-
maining 12 had normal gastro-intestinal studies. 
TESTS OF IMMUNE FUNCTION 
Immune function i.e. neutrophil killing time, chemotaxis, phagocytosis were undertaken in 
2 patients who had extensive, severe cutaneous disease (cases 39, 45). Neutrophil killing 
time was 0% ( 100% in control), but with normal chemotaxis and phagocytosis in case 45. -
Neutrophil function in case 39 was normal. 
Tests for connective tissue disorders (polyarteritis nodosa, systemic lupus erythematosus, 
mixed connective tissue disease) were undertaken in patient 30, but these were all negative 
or normal at the time of writing. 
HISTOLOGY 
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Reports of histologic examination of the PG ulcers were available in 30 patients, with 53 
specimens available for examination (although one was able to judge from dates on patho-
logy reports when in the disease course specimens were taken, the site, stage of develop-
ment or whether subsequent biopsies were taken from the same lesion or "new" lesions, was 
unavailable.) 
Predominance of neutrophils in the upper dermis was demonstrated in 24 specimens. 
A mixed, chronic inflammatory dermal infiltrate (plasma cells, neutrophils, mononuclear 
cells and giant cells were present in 15 specimens). 
A necrotizinglleucocytoclastic vasculitis involving the small vessels of the upper dermis was 
demonstrated in 8. 
One specimen (from case 40, who clinically fitted the superficial granulomatous form of 
PG) demonstrated the described granulomatous histology, i.e. the granulomas were formed 
in 3 layers: the innermost layer consisted of neutrophils, the surrounding layer was com-
posed of giant cells and histiocytes; and the outermost layer consisted of plasma cells with 
eosinophils. 
Twelve specimens had panniculus present, 6 demonstrating mild involvement of the subcu-
taneous fat, while in the remainder, the panniculus was uninvolved. 
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THERAPY 
Details of therapy are shown in Tables 5 and 6 
TABLE 5: THERAPY 
NO. OF REMISSION REMISSION PERSISTENT 
PATIENTS ONRx OFFRx PGONRx 
STEROID 
ALONE 10 2 6 2 
STEROID+ 
OTHER AGENTS 28 14 7 7 
OTHER AGENTS 6 3 3 
UNKNOWN 1 
SKIN GRAFTS 4 2 1 1 
Thirty-one of 45 patients (84.4%) obtained remission of their skin ulceration on systemic 
cortiosteroids. Five of these remitted after pulse therapy (cases 5, 17, 20, 31, 40) while the 
remainder responded to oral prednisone in dosages that varied between 40 and 80mg daily, 
except for 1, (case 27) who required up to 150mg/daily. 
Three patients ( 6.6%) are known to have obtained complete remission without systemic 
corticosteroids: 
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Case 16- healed after a protracted course of topical corticosteroid ointment. 
Case 22 - remitted after a course of cytotoxic treatment. 
Case 36- responded to dapsone therapy. 
Details of therapy were lacking in one patient (case 23). 
Time for complete remission of ulceration after initiation of corticosteroid therapy varied 
between 3 weeks and 3 years. In the corticosteroid responsive group, 30 obtained remission 
under 16 weeks, while the remaining 3 ran more chronic, protracted courses (cases 1, 3, 27). 
Ten (22.2%) patients failed to remit. Seven of these, despite administration of systemic cor-
ticosteroids (cases 2, 21, 26, 33, 39, 44, 45), while the remainder: 
Case 12- Refused corticosteriod therapy. Continued with active disease on homeopathic 
medication. 
Case 18 - succumbed to underlying disease before definitive treatment could be instituted. 
Case 42 - had active lesions of PG which had partially responded to oral tetracycline treat-
ment, at his last recorded visit (figure 17). 
Four patients (cases 5,10,33,34) with resistant or extensive skin lesions had skin grafts under 
corticosteroid cover. The grafts were successful after the first attempt in cases 5 and 34. 
Case 10 eventually remitted after several procedures. However, case 34 had persistent lo-
calised PG despite repeated skin grafts. 
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igure 17: PG on oral tetracycline (case 42) 
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!fABLE 6: TREATMENT 
PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
1. G.S. 60mg Sulfasalazine Osteoporosis Alive. Off Rx. 
4G Hypertension No PG for2 
6MP75mg Cushingoid years. Bowel 
Myopathy inactive for 
18 months. 
2. L.J. 125mg 6MP75mg Cushingoid Alive with 
Sulfasalazine persistent peri-
3G neal ulceration. 
IBD stable on Rx. 
Off steroid Rx. 
3. M.I. 60mg Sulfasalazine Cushingoid Alive. No PG for 
4G Osteoporosis 3 years. IBD 
stable on Rx. 
4. M.I. 60mg SuI fa sal azine Nil Alive. No PG for 
4G 1 year. Off Rx 
Dapsone lOOmg 
5. N.S. 1G Clofazamine Diabetes Alive. No PG for 
300mg mellitus. 11 months on no 
Sulfasalazine Hypertension Rx. IBD stable 
4G Osteoporosis onRx. 
Cushingoid 
53 
PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
6. L.N. 60mg Cushingoid Alive. No PG for 
Hypertension 6 months on 
corticosteroid. 
IBD stable on Rx. 
7. R.H. 40mg Nil Alive. No PG for 
7 years. IBD 
stable. Off Rx. 
8. c.c. 60mg Nil Alive. No PG for 
2 years.lBD 
stable. Off Rx. 
9. A.N. 40mg 'Nil Alive. No PG for 
9 years. IBD/CAH 
- stable on Rx. 
10. A.G. 80mg Cushingoid Alive. No PG for 
Myopathy 12 years. lBD 
stable. Off Rx. 
11. P.C. 60mg Unknown Unknown. Last 
record 12/1/79; 
alive. Active PG 
on Prednisone. 
12. R.N. Homeopathic None Persistent PG. 
Active IBD. 
13.E.W. 40mg Nil Alive and well. 
No PG. OffRx. 
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PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
14.G.S. 40mg Dapsone lOOmg Nil tecotded Unlalown. Last 
Clofazamine ·record 9/1/84. 
300m g. NoPGforS 
months. Off Rx. 
RA stable on NSAI. 
15. s.s. 60mg Sulfasalazine Mania Alive. No PG for 
4G.(added on Cushingoid 1 year. Off RX. 
second relapse) Osteoporosis RA stable- ofi Rx. 
16. S.A. Topical Nil Alive. No PG for 
corticosteroid 7.5 years. RA 
stable on Rx. 
1/.P.M. 1G Cyclophos- Mania Unknown. Last 
phainide 1G. Diabetes record 25/9/87. 
mellitus. NoPG.On 
maintenance 
Prednisone. 
18.P.H. Cytosine Deceased (19/2/81) 
. ' 
VP16 due to underlying 
Adriamycin leukaemia. 
Persistent PG. 
19. W.J. 40mg Nil recorded Deceased (myelo-
dysplasia) At time 
of death no PG for 
3 months. Off Rx. 
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PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
I 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
20.M.S. lG Nil Deceased (3/89) 
(myelofibrosis) · 
At time of death· 
no PG for 2 years. 
On Rx for under-
lying disease. 
21. P.S. 40mg Clofazamine Osteoporosis Deceased 2717/88 
300mg. Fracture right from underlying 
Methotrexate neck of femur myelodysplasia. 
5mgweekly Persistent PG at 
Sulfasalazine time of death. 
lG. OnRx. 
22. Cytosine Nil Deceased from 
Arabinoside underlying 
doxorubicin leukaemia. Active 
PG at time of 
death. 
23.M.B. Unknown. Unknown Unknown. Last 
record 26/1/1972. 
Active PG. Rx not 
recorded. 
24.A.V. 60mg Azathioprine Cushingoid Alive. No PG for 
lOOmg 3 months. 
Colchicine lmg CAH stable on Rx. 
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PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
25.A.B 20mg Nil recorded Deceased (due to 
complications of CAH). 
Status of PG 
unknown. 
26.F.B. 40mg Azathioprine Cushingoid Alive. Persistent 
lOOmg ulceration on Rx. 
Colchicine lmg CAH unstable - on 
Rx. 
27.A.L. 150mg Clofazamine Cushingoid Alive. No PG for 
(300mg) Bronze pigment~ 1 year. On 
Doxycycline ation. maintenance 
(lOOmg) corticosteroid. 
Etretinate Takayasu's 
(75mg) stable. 
Sulfasalazine 
(4G) 
Colchicine 
(l,Smg) 
Cyclosporin 
(lOOmg) 
'-
Anti-TB drugs 
Dapsone( lOOmg) 
28. S.P. 80mg Clofazamine Cushingoid Deceased. Post-
300mg. op septicaemia. 
'\ 
At time of death, 
noPG. 
PATIENT PREDNISONE 
(max. daily 
dose) 
29. N.B. 60mg 
30. M.M. 60mg 
31. N.M. 1G 
32. W.L. 40mg 
OTHER AGENTS 
(daily dose) 
Clofazamine · 
300ing. 
Dapsor:e 200mg 
Dapsone lOOmg 
Minocycline 
200mg 
Cyclophospha~ 
mide 1G. 
Sulfasalazine 
4G 
Minocycline 
200ing 
Sulfasalazine 
4G. 
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COMPLICATIONS STATUS IN 
NOVEMBER 1990 
Hyperpigment- Unknown. Last 
ation. record 27/7/87: 
NoPGonRx. 
Behcets in 
remission. 
Cushingoid Alive. Stable PG 
Osteoporosis and vasculitis. 
on maintenance Rx. 
Headache and Alive. PG healed 
vertigo for 1 week on 
maintenance 
prednisone. 
Nil Deceased. 
(30/10/1971) 
Total organ fail-
ure (cause not 
established). 
Active PG at 
time of death 
despite Rx. 
j 
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PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
33.P.O. 80mg Tetracycline Cushingoid Alive. Active 
1 G. Erythro- Osteoporosis lesions of PG. 
mycin 500mg Fractures of On maintenance 
Clofazamine metatarsals, prednisone 20mgl 
300mg achilles daily 
Azathioprine tendon 
lOOm g. 
34. D.F. 40mg Dapsone 40mg Cushingoid Alive and well. 
No PG for 3,5 years. 
OffRx. 
35. R.J. 40mg Minocycline Cushingoid Alive with 
200mg active lesions of 
PG. On Rx with 
prednisone and 
minocycline. 
36. P.E. Dapsone 200mg Nil recorded Unknown. Last 
record January 87 
- Alive and well. 
No PG for 6 
years. 
37. C.B. 60mg Clofazamine Nil Unknown. Last 
300mg recorded visit 
10/3/80. Alive and 
well. No PG for 
1 year. Off Rx. 
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PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
38.M.N. 60mg Clofazamine Cushingoid Deceased. 
300mg Last record 
Dapsone lOOmg 24/10/78 - one 
small PG ulcer on 
Rx. 
39.A.M. 40mg Clofazamine Cushingoid Deceased 
300mg · (27/12/78) 
Sulphapyridine Extensive 
lG lesions of PG 
Dapsone 150mg present at time 
Imuran 40mg of death 
40. M.B. lG Minocycline Headache Alive. PG healed 
200mg for 1 week. On 
Sulfasalazine prednisone 
4G 60mg/daily. 
41. M.A. 30mg Sulfasalazine Cushingoid Alive and well. 
4G No PG for 13 
years. Off Rx. 
42. N.S. Tetracycl.ine Nil Unknown. Last 
lG record 17/2/75. 
Active PG on 
tetracycline. 
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PATIENT PREDNISONE OTHER AGENTS COMPLICATIONS STATUS IN 
(max. daily (daily dose) NOVEMBER 1990 
dose) 
43. J.T. 80mg Diabetes Unknown. Last 
mellitus record 21!5/71. 
No PG on predni-
sane lOmg/daily. 
44. T.P. 160mg Clofazamine Diabetes Death on. 
300mg mellitus (3/12/89) due to 
SuJfasalazine Cushingoid diabetic coma 
4G Osteoporosis Active lesions 
Azathioprine of PG present. 
lOOmg 
Thalidomide 
200mg 
45. G.T. 60mg Clofazamine Cushingoid Deceased 
300mg (26/10/1980) 
Active lesions 
of PG at time of 
death. 
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CHAPTER FIVE 
DISCUSSION 
A retrospective study of this nature is prone to errors and ommissions. In this case, it is 
made even more difficult by the fact that pyoderma gangrenosutn is largely a clinical diag-
nosis where objective laboratory criteria are lacking. Despite this, adequate information 
was available in 42 of 45 patients collected in this series. The number of patients i.e. 45 diag-
nosed over a twenty year period, is likely to be an adequate representation of the true pre-
valence of this disorder at GSH, based on the experiences of workers in the field 
2,3,4,5,56, 78,126 
On average, 1-3 new cases of PG were recorded annually in the GSH series. This number, 
despite an increased awarenes of the condition in recent years, has remained constant. The 
relatively high number of patients in two series (both from the Mayo clinic), probably re-
flect a higher rate of referral to this major medical centre3,4. 
CLINICAL FEATURES 
In the GSH study, the age and sex incidence conformed with other reported studies, with 
PG occurring mainly in adults of all ages. This study also reflected the relative rarity of PG 
in children and the very elderly a:s previously reported. There were no distinguishing fea-
tures in the various age groups in either the published series or in the GSH series. This is re-
flected in the childhood cases seen at GSH, which varied from the localised, atypical PG of 
head and neck (figure 7, case 34) that remitted completely after a short course of oral corti-
costeroids, to extensive, fulminating disease as in case 39, who ultimately succumbed to his . 
cutaneous disease despite multiple therapies, including corticosteroids. The third child in 
this series (case 26) had an associated CAH and was stable on therapy at time of writing. Of 
the two patients over 70 years (cases 20, 23), both had limited disease and both had under-
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lying haematological disorders. PG remitted in case 20 after pulsed methylprednisolone, 
but the outcome in case 23 is unknown. 
The pattern of the clinical course in PG was not emphasized in published series i.e. whether 
patients followed an acute, rapidly progressive course or a more chronic, indolent one. This 
is probably due to the fact that the clinical pattern offers very little in the way of predictive 
value with regard to response to therapy or ultimate prognosis. This was borne out in the 
GSH study, where 37 patients ran an acute, relapsing..,rapidly progressive course while the 
remaining 8 were chronic and slowly progressive, yet response to therapy and ultimate out-
come was extremely variable in both groups. Extensive cutaneous involvement is one factor 
which may be a poor prognostic indicator (a feature not emphasized in previously published 
series). In the GSH study, six patients (cases 27, 32, 38, 39, 44, 45) had greater than 50% cu-
taneous involvement, and all of them ran problematic courses. Of interest, all were of the 
idiopathic group except for case 27 who had associated Takayasu's arteritis. Five, are de-
ceased (either as a direct result of their cutaneous involvement or due to complications of 
treatment), while the remaining patient with Takayasu's arteritis, after a fulminating course, 
was in remjssion on therapy at the time this study was undertaken. The poor prognosis in 
this group is worth noting. 
ORALPYODERMA GANGRENOSUM 
PG of the oral cavity is uncommon, judging from the dearth of published case re-
ports36·37·38. In these individual case reports, the diagnosis of oral PG was aided by the con-
comitant presence of typical cutaneous lesions of PG. In the published series to 
d 1 2 3 56 78 126 l PG · · d f · f h d · Th · ate ' ' ' ' ' , ora IS not mentwne as a eature m any o t e reporte patients. IS 
may indicate the rarity of oral involvement or a failure to recognise that oral involvement 
(if it was present) was that of PG. 
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In the GSH series, 4 patients (8.9%) were documented as having oral involvement (cases 1, 
9, 26,39). The oral ulceration in cases 1 and 26 have been retrospectively diagnosed as oral 
PG (following review of their records for this study). The ulcerative process in case 1 had re-
sulted in complete destruction of the uvula, and highlighted the importance of considering 
oral PG in cases of severe oral ulceration where histologic proof of vasculitis or malignancy 
is lacking and bacterial, fungal and viral cultures are negative. This may lead to earlier and 
consistent therapy and avoid the kind of destruction that was seen in this patient. Repeated 
biopsies (as happened in case 1, who for many years was considered to be suffering from 
"limited Wegener's granulomatosis"), may also be avoided. 
Case 26 presented with hoarseness several years after cutaneous PG was diagnosed. The 
hoarseness was associated with a flare of the cutaneous lesions as well as the underlying 
CAH. Repeated otolaryngologic examinations and biopsies revealed oropharyngeal ulcera-
tion and non-specific inflammatory changes of the vocal cords. She failed to respond to sev-
eral courses of antibiotics and local care and only after adequate, consistent therapy with 
corticosteroid and immunosuppressives for the concomitant flare of CAH, did the oral ul-
cers and hoarseness resolve. (The possibility that the oral and laryngeal ulcers were due to 
PG was considered only after this study was undertaken). There has been only one pub-
lished report of laryngeal involvement by PG36. That subject, (who had an associated IBD 
and cutaneous PG), had intranasal as well as oral and laryngeal involvement. Shere-
sponded favourably to a course of pulse methyl prednisolone. 
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In the GSH study, the oral involvement (which resolved after oral prednisone) in case 9, 
best fitted the description for pyostomatitis vegetans (this patient had associated CUC). In 
case 39, however, details of the oral ulcers were lacking from the patient's records although 
post-mortem examination revealed evidence of severe oral involvement. 
One other patient in the GSH series, case 35, had intranasal as well as lung involvement 
and has been tentatively diagnosed as nasal and pulmonary PG after preliminary examin-
ations undertaken by the otolaryngology and respiratory departments appear to have ex-
cluded Wegener's granulomatosis and infections. In addition, this patient was pregnant 
when PG recurred for the first time. There was no deterioration in PG as a result of the 
pregnant state, nor did the therapy with prednisone interfere with foetal development. PG 
in pregnancy has not previously been discussed in the literature. A firm diagnosis of nasal 
and pulmonary PG could only be made after completing further examinations and biopsies. 
Her cutaneous lesions have remained in remission for 12 weeks (at time of writing) on 
8mgldaily methylprednisolone. If Wegener's granulomatosis and all infections are positively 
excluded in this patient, intranasal and pulmonary PG has to be strongly considered, in 
which case she may benefit from pulse methylprednisolone (as did the patient in the only 
published report of intranasal involvement)36, or a higher dose of corticosteroid. In a report 
of pulmonary involvement with PG the patient responded favourably to oral prednisone 
1mglkglday after 16 weeks127. There are two other reports of pulmonary involvement with 
PG, where the nature of the pulmonary condition remained undiagnosed128'129, but where 
clinical and radiologic abnormalities returned to normal with steroid therapy. Physicians 
should be aware of the existence of sterile neutrophilic lung collections to avoid unnecess-
ary delay'in diagnosis and institution of therapy. 
Three patients (cases 2, 10, 28) had severe perineal involvement. These patients empha-
sised the care that should be taken when surgery is embarked on in this area. Preparation 
with hyperbaric oxygen prior to surgery has been recommended104. Psychological and emo-
tional support in such cases cannot be overstressed49. Case 2, a young female, who has an as-
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sociated Crohn's disease and a permanent ileostomy, had persistent perineal disease (figure 
12) and cavitating ulcers at the time of writing while, in case 28, (who had associated en-
dometriosis), complete obliteration of the vaginal vault was unavoidable. Case 10, a male, 
with a permanent stoma for chronic ulcerative colitis had severe perineal ulcers, which for-
tunately healed well after several plastic surgical procedures and prolonged oral corticoste-
roid therapy. PG in the perineal area, like oral PG, may not be readily recognised, 
particularly in the face of IBD. 
ATYPICAL PC 
Scant attention is paid to the atypical forms of PG in the majority of published series but 
this may reflect the rarity of these forms. In the GSH study, six patients ( 13.3%) fulfilled the 
criteria for atypical forms of PG. They included the well documented but uncommon super-
ficial, bullous variant of PG described with leukaemic and pre-leukaemic states in two pa-
tients ( 4.4%) (one associated with myelofibrosis, while the other was regarded as idiopathic 
-patients 20 and 32 respectively). The true prevalence of this atypical form is unknown. 
(Even the largest of the more recently published series of PG makes no mention of this vari-
ant having occurred in any of their 86 patients{ 
The atypical PG of head and neck also appears to be uncommon. Six patients (24%) had in-
volvement of the head and neck in a series of 25 patients reported by Snyder24. Prystowsky 
et al reported that 1 of 21 patients ( 4.8%) had atypical PG of head and neck 78• Attention is 
not drawn to this variant in other published series. In the GSH study, 3 patients (6.7%) 
were regarded as suffering from atypical PG of head and neck (cases 5, 33, 34 ). Case 5, who 
had acute, rapidly progressive PG of the neck associated with IBD, resolved on pulse and 
,. 
oral corticosteroids; case 33 failed to remit despite pulse and chronic oral corticosteroid 
therapy spanning a period of nearly 18 years, while case 34, a young boy with indolent le-
sions, responded favourably after oral corticosteroid therapy was instituted. 
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Finally, the one other variant of PG described in the literature, and reported by Wilson-
Jones and Winkelmann i.e. the localized vegetative form of PG46 occurred in one patient in 
the GSH series (case 40). Since this report, there have been no further published reports of 
this variant. The GSH patient illustrated both the clinical (figure 5) and histological pattern 
of this variant. In the Wilson-Jones report46, it is stated that this form appears to have a bet-
ter prognosis with the majority of patients resolving without systemic corticosteroid and, 
therefore, distinction from the other clinical variants may be indicated. However, in the 
GSH study, case 40 required pulse methylprednisolone for control, once again emphasisi~g 
the variability in all forms of PG. 
ASSOCIATED DISEASE 
PG is frequently associated with a systemic disease (mote than 50% in most published 
series). In the GSH study, 69% had an associated systemic disease. 
In the GSH series, as in the majority of published reports, INFLAMMATORY BOWEL 
DISEASE was the most frequent association (cases 1-13). However, unlike in the other pub-
lished series and reports5•54•74•75•77•130•131, Crohn's disease (regional ileitis), rather than 
chronic ulcerative colitis, was more frequently encountered. This may reflect the high refer-
ral rate of Crohn's disease to this centre, where a special interest in regional enteritis exists. 
The patients in this group varied widely with regard to clinical presentation, absence or 
presence of bowel activity at time of development of PG, response to therapy and clinical 
course. This is in keeping with experience elsewhere54•74•75•77•130•131. 
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The contentious issue of bowel resection for cutaneous disease102 was highlighted by case 2, 
who had persistent perineal disease at time of writing, despite radical surgery (a total colec-
tomy, followed later by a proctectomy). This issue was addressed by Talansky et al102, who 
on a retrospective study of 9 patients with active PG at time of operation for inflammatory 
bowel disease showed two patterns of post-operative healing: (1) Prompt healing within 2 
months, occurred in five patients with moderate to severe inflammatory bowel disease. (2) 
Skin disease persisted in four others, healing only after a year. Three of these patients had 
mild ulcerative colitis, and in them, the operation was carried out in the hope of curing 
crippling pyoderma gangrenosum. Another group of authors, Levitt et aJ 131, have reported 
that in 13 patients with PG who underwent surgical resections (total of 15 procedures), PG 
healed promptly in five cases, only with additional therapy in five, and very slowly or not at 
all in five. They concluded that healing appeared to be unrelated to the timing and extent of 
. . I . Th. . . . d b h bl" h d 34 75 103 Th. mtestma resection. IS opm10n 1s supporte y ot er pu 1s . e I:eports ' ' . e 
general consensus would thus appear to be that intestinal resection may not necessarily heal 
the PG of IBD and that bowel activity rather than cutaneous disease, should be considered 
when surgery is contemplated. This contrasts with the earlier literature which generally sup-
ported the notion that definitive surgery of bowel disease favourably influenced the skin le-
. 132 
swns . 
Another problem highlighted by case 2 is distinguishing perineal Crohn's disease from peri-
neal PG52. In the former, surgery may be embarked on to exclude occult abscesses or 
sinuses, but if the lesion happens to be PG, this may further exacerbate the existing condi-
tion. Under these circumstances, examination under anaesthesia by an experienced surgeon 
is paramount to avoid the risk of unnecessary surgical trauma. Except for Maule's letter52, 
the problem of distinguishing perineal Crohn's disease from perineal PG has received scant 
attention from gastroenterologists and ano-rectal surgeons, judging from the dearth of pub-
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lished reports on this issue. Given the debilitating course (physical and emotional) of PG in 
the perineal area, its distinction from perineal Crohn's disease warrants further attention. 
Patients with perineal PG may benefit from pulse methylprednisolone therapy. 
Parastomal PG occurred in five patients in the GSH study. This relatively high number of 
patients may indicate an increasing awareness of this entity by gastroenterologists, dermato-
logists and stomatherapy nursing staff at this hospital since attention was first drawn to it by 
McGarity et al in 198447. Since this report, there has been one further report48. Parastomal 
PG may be difficult to recognise since parastomal dermatitis, ulceration and abscesses are 
common. The diagnosis, as for PG elsewhere, should be one of exclusion (particularly infec-
tion). The ulcers of PG in this area may not show the typical appearance of PG elsewhere 
/ 
on the skin, but a compelling feature for PG observed in the GSH series, was the intense 
pain at the site, followed by a dramatic reduction in intensity (sometimes within hours) 
after the introduction of corticosteroids. This prompt reduction in pain is not discussed in 
McGarity's report where oral prednisone was prescribed in 3 patients with parastomal 
PG47. The one other report of parastomal PG that is available, described the successful use 
of a wound gel rather than systemic therapy in a patient with parastomal PG48. 
The overall prognosis in the IBD group in the GSH series was good. (10 of the 13 patients 
were alive and well at time of writing, with no active disease, either on maintenance or off 
treatment altogether; one (case 13) had persistent disease on homeopathic medication; fol-
low-up in one (case 11) was unavailable but at the last recorded visit the ulcer was showing 
signs of healing, and case 2 had persistent perineal disease). It would appear that PG in as-
sociation with IBD may run a less severe course. 
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ARTHRITIS is an often quoted association with PG, but some confusion exists as to the 
true prevalence of sero-positive rheumatoid arthritis associated with PG as opposed to 
other forms of arthritis i.e. sero-negative rheumatoid arthritis, arthritis of inflammatory 
bowel disease, ankylosing spondylitis and osteoarthritis. In only 2 series, was close attention 
paid to the forms of arthritis occurring with PG4•56. In the latter series, Holt et al, drew at-
tention to a unique form of erosive, destructive polyarthritis associated with PG. Unfortu-
nately, in the GSH study, accurate documentation of the presence of arthritis was available 
in six patients only. Despite this, it would appear that none of the patients in the GSH series 
suffered from the seronegative erosive, destructive form of polyarthritis described by Holt 
et al and thought to be peculiar to patients with PG56. A more careful examination of joints 
in future patients with PG may yield more accurate figures. 
Cutaneous vasculitis in rheumatoid arthritis may be of grave prognostic significance133. PG 
in rheumatoid arthritis has in the past been distinguished from rheumatoid vasculitic ulcers 
on morphological grounds and the absence of vasculitis on histology, yet this distinction 
may not be valid in the light of vasculitis having been demonstrated in lesions diagnosed as 
PG80. An overlap of cutaneous vasculitis and PG may exist, as illustrated in a patient in the 
GSH series (case 17) who had digital infarcts, small haemorrhagic infarcts of face, mono-
neuritis multiplex and large cutaneous ulcers diagnosed as PG by the dermatologists. A 
more careful look at the clinical presentation and histologic picture in patients with PG and 
rheumatoid arthritis may help to clarify this issue. 
An unusually high association of HAEMATOLOGICAL DISORDERS with PG (13%) was 
found in the GSH study (6 of 45 patients). This may reflect the high index of suspicion dis-
played by the haematologists at this hospital, who in 1985 reported a patient with PG in as-
sociation with acute myeloid leukaemia29. The prevalence of PG in association with 
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leukaemic and pre-leukaemic conditions in other series is low (1 of 86 patients in the Mayo 
I. . . 1 f 10 . . h W 'k . )4126 A . 1 d c m1c senes, o pat1ents m t e a1 a to expenence ' · . s prevwus y reporte , pa-
tients with myeloid malignancies who develop pyoderma gangrenosum have a particularly 
poor prognosis25•30. This is reflected in the GSH series, where all six patients have died 
from their underlying disease. In 3 patients (cases 18, 22, 23), the course was rapidly down-
hill, while the remaining 3 (cases 19, 20, 21), who ran more indolent courses, were plagued 
by ill-health and debility throughout their illness. Four patients died with persistent cuta-
neous disease (cases 18, 21, 22, 23), while in the remaining 2 (cases 19, 20), the PG lesions 
had remitted on oral and pulse corticosteroid therapy, respectively. 
CHRONIC ACTIVE HEPATITIS (CAH) is an uncommon but well documented associ-
ation with PG6,7. Two of the 86 patients (2.3%) with PG in the Mayo clinic series suffered 
from CAH4. There were none in the other published series1•2•3•5•56•78•126. The GSH study re-
vealed an unusually high number ofpatients with CAH (4 of our 45 patients, 8.9%). One of 
these patients had CUC as well (Case 9). Some confusion with the hepato-cutaneous syn-
drome134, a chronic skin eruption of trunk and limbs associated with CAH and charac-
terised by inflammatory papules with central crusting, which on healing, leave depressed 
scars, and PG, arose in case 25 at her initial presentation. However, as the lesions evolved 
into more typical lesions of PG which lacked the specific histology described for the hepato-
cutaneous syndrome (i.e. a dermal infiltrate of lymphocytes and histiocytes with patchy 
quantities of fibrin in the sub-basal region of the skin), a confident clinical diagnosis of PG 
was made in this patient. 
The relatively high number of cases of PG is association with CAH in the GSH series, again 
may reflect an increased awareness of this association on the part of hepatologists and der-
matologists at this institution. 
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MONOCLONAL GAMMOPATHIES (particularly IgA) have been reported in association 
. h PG . h . . f . 56 71 78 87 Th . .d f I I wit . wit mcreasmg requency m recent years ' ' ' . e mc1 ence o monoc ona 
gammopathy with PG varies in different series. 
Ten percent of patients with PG (9 of 86) were found to have a monoclonal g~mmopathy in 
the series reported from the Mayo clinic4· Holt et al and Prystowsky eta! reported IgA gam-
mopathies occurring in twenty percent of their patients i.e. 3 of 15 and 4 of 21 patients re-
spectiveli6·78. None of the 15 patients studied by Lazarus and Hickman had a monoclonal 
gammopathi. Kyle and Greipp have also reported that ten to twenty percent of patients 
with PG have a monoclonal gammopathy135. 
In the GSH study, only one patient had an IgA gammopathy on immunoelectrophoresis 
(case 31). This may be due to the fact that immunoelectrophoresis has as yet, not been part 
of the routine investigations in PG at this institution. Thus far, reports indicate that the ma-
jority of monoclonal gammopathies associated with PG tend to run a benign course 71•78. 
The importance of the association remains unclear, but with reports of some patients de-
veloping myeloma later on in their course 71 , long-term observation of these supposedly be-
nign monoclonal gammopathies is probably indicated. Holt and Prystowsky recommend 
that se rum protein electrophoresis be done in every patient with PG 71•78. Kyle and Greipp 
have pointed out that a small monoclonal peak may be missed on serum protein electro-
phoresis and therefore perhaps immunoelectrophoresis should be clone in all cases of 
PG 135. In the GSH series, immunoelectrophoresis was not clone in those patients where 
serum protein electrophoresis was normal or a polyclonal acute phase response was ob-
tainecl. With increased awareness of the association of monoclonal gammopathies with PG, 
the recognition of such patients at GSH may well increase, particularly if immunoelectro-
phoresis is routinely requested on all cases of PG. 
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The significance of less commonly associated diseases remains speculative. In the GSH 
study, there was 1 patient each with Behcet's syndrome (case 29), Takayasu's arteritis (case 
27), systemic leucocytoclastic vasculitis (case 30, figure 18) and endometriosis (case 28). 
'igure 18: PG associated with systemic vasculitis (case 30) 
This reflects the uncommon occurrence of these rarer disorders with PG and confirms the 
experience of series previously reported in the literature. The patient with endometriosis 
(case 28) in the GSH series, is thought to be the first patient in whom endometriosis has 
been described in association with PG50. The role of endometriosis in the pathogenesis of 
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PG in this patient remains speculative. The patient with Behcet's syndrome ran a chronic in-
doleot course that required relatively low doses of oral prednisone (lOmg/daily mainten-
ance) to control, yet when he stopped taking his medication, he would almost immediately 
experience a flare of the cutaneous disease. Skin lesions, typical of PG, have been reported 
. B h ' d 66 136 137 M d C . 1· . I d h. 1 . I Ill e cet s syn rome. ' ' . unro an ox report an extensive c mica an 1sto og1ca 
overlap between pyoderma gangrenosum and Behcet 's syndrome66. 
<'igun~ 19: Extensive cutaneous disease in a patient with Takayasu's arteritis (case 27) 
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Case 27, who had Takayasu's arteritis, had extensive, fulminating disease (figures 19 and 20) 
and yet, after prolonged corticosteroid therapy attained complete remission. (At the time of 
writing she had been in remission for one year and was stable on a maintenance dose of 
prednisone lOmg/daily) . PG in association with Takayasu's arteritis has been reported with 
greater frequency from Japan, where the increased incidence remains unexplained. No 
correlation between site of arterial obstruction and site of PG was detected in the 96 
Japanese cases thus far reported, although it has been suggested that peripheral circulatory 
. ff. . 1 I 90 msu JCiency may pay a roe . 
<' igu1·e 20: Extensive cutaneous disease in a patient with Takayasu's ~~~·tel"itis (case 27) 
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Case 30 demonstrated both cutaneous and renal vasculitis. This patient presented with 
symptoms of a systemic illness (mass loss, fever, arthralgia, anaemia), then subsequently de-
veloped haemorrhagic looking vesiculo-pustules, some of which evolved into ulcers that 
were diagnosed by dermatologists as that of PG (figure 18) (histology of a vesico-pustule 
demonstrated leucocytoclastic vasculitis). Leucocytoclastic vasculitis has been previously re-
ported in the literature57•59. In th~ first, leucocytoclastic vasculitic skin lesions preceded the 
development of PG by 8 years, while in the second the vasculitic lesions preceded PG by 3 
years. In both patients, evidence of systemic involvement was lacking. In the second report, 
the patient had an associated chronic pyelonephritis. The patient in the GSH study ap-
peared to be suffering from a vasculitic syndrome which had not yet clearly been defined 
(the attending physicians expect this patient to evolve into SLE with time). Renal vasculitis 
in association with PG has not previously been reported but an association with systemic 
lupus erythematosus (SLE) has92. 
( 
Of note, 3 patients in. the GSH study developed pulmonary tuberculosis sometime during 
the course of their illness, but this may not be a significant association with PG in the face 
of the high incidence of pulmonary tuberculosis seen in the Western Cape. 
Of these 3 patients, the first presented with pulmonary tuberculosis at the same time he de-
veloped PG (case 45 ), the second had evidence of old healed pulmonary tuberculosis at 
presentation of PG (case 44 ), while the third patient developed signs and symptoms of TB 
while on corticosteroid therapy prescribed for PG and the associated CAH (case 26). 
Lazarus and Hickman reported 1 patient with pulmonary tuberculosis in association with 
PG5. 
HISTOPATHOLOGY 
Su et al, who examined the largest number of specimens taken from lesions of PG, con-
cluded that a lymphocytic vasculitis was frequently demonstrated when the biopsy was 
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taken from the advancing, peripheral zone of erythema, while a mixed inflammatory infil-
trate and abscess formation was found in those cases where specimens were taken from the 
undermined edge or floor of the ulcer55. In Su's study, it is not clear whether the early ve-
siculo-pustular lesions of PG were biopsied. Callen found that these early pustular lesions 
always demonstrated a marked neutrophilic infiltrate in the dermis which justified the classi-
fication of PG under the neutrophilic dermatoses5. 
In the GSH study, 53 specimens from 30 patients were available for study, none of which 
showed a lymphocytic vasculitis. This may indicate that none of the biopsies were taken 
from the peripheral zone of erythema present adjacent to the undermined edge, as advised 
by Suet a155. Wong and Greaves support the view that leucocytoclastic vasculitis is a patho-
genetic factor in PG 57. Neutrophils were the predominant cells in 24 specimens ( 45.3%) 
(including those where a leucocytoclastic vasculitis was demonstrated). In Su's study, 36spe-
cimens (55%) demonstrated neutrophils. It is now accepted that leucocytoclastic vasculitis 
is often present if the very early vesiculo-pustular lesion of PG is biopsied57. Leucocyto-
clasis was demonstrated in 3 of the 66 specimens studied by Su et al i.e. 5 percent55. It is not 
clear whether fibrinoid necrosis was present as well in these specimens. It is interesting that 
in the GSH study, as many as 8 of the 30 patients biopsied (26.6%) demonstrated leucocyto-
clastic vasculitis. In these 8 patients (cases 3, 4, 30, 31, 34, 37, 41, 43) biopsies were taken 
from clinically characteristic lesions of PG in 7, while the remaining patient (case 34 ), 
presented with the atypical variant of PG of the head and neck. In patient 30, leucocytoclas-
tic vasculitis was demonstrated in both skin and kidney. 
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It would thus seem that histologic evidence suggests that the initiating event in PG may be a 
vasculitis, but until such time as a large enough series is undertaken, this supposition re-
mains speculative. 
IMMUNOPATHOLOGIC STUDY 
Documentation of direct immunofluorescence having been done on specimens taken from 
lesional or peri-lesional skin of patients with PG, was lacking in the GSH study. 
Direct immunofluorescence was done in two studies 78,138 . In the first, Prystowsky et al did 
not detect any deposition of complement or immunoglobulin in biopsies of the leading edge 
of ulcers of PG, while Powell et al described positive immunoglobulin or complement pres-
ent in lesional skin of 61 percent of 51 cases studied by immunofluorescence. This seems to 
indicate that at this stage, this examination is not particularly helpful in elucidating the pa-
thogenesis of PG. 
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SPECIAL INVESTIGATIONS 
Hypersensitivity skin testing. 
Judging from the literature review, delayed hypersensitivity tests as a routine investigation -
are of questionable value in PG 78. In the Western Cape, however, the mantoux intradermal 
test is probably indicated in all patients with PG in view of the high incidence of tubercu-
losis in this region, as the majority of patients with PG will require corticosteroids. 
Radiology 
The value of chest radiography is not discussed in the l.iterature, although the recent reports 
of lung involvement in PG127•128•129 highlight the value of this investigation. In the Western 
Cape, where the prevalence of pulmonary tuberculosis is high, chest radiography is of par-
ticular importance, especially in patients embarking on corticosteroid therapy. Preliminary 
investigations in case 35 suggest that her pulmonary lesions may be sterile neutrophilic col-
lections associated with PG. 
The value of barium studies of the upper and lower gastro-intestinal tract (possibly com-
bined with sigmoidoscopy or colonoscopy) in the patient without symptoms of bowel dis-
ease is controversial. Perry, in one of the earlier series, felt that, in view of the frequent 
association of chronic ulcerative colitis with PG, all patients with PG should have a com-
plete gastro-intestinal radiological screen3; Patients who did not have a proctoscopic exam-
ination or a colon roentgenogram were placed in the category of inadequate gasto-intestinal 
studl. In Perry's study, 44 of 62 patients (71%) had adequate gasto-intestinal studies and of 
these 31 were found to be suffering from chronic ulcerative colitis (of these 25 had colitis 
prior to onset of PG). Only four (9.1 %) asymptomatic patients were found to have radio-
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logical evidence of bowel disease. In the GSH study, adequate bowel studies were under-
taken in 15 patients who had no symptoms relevant to the bowel. Of these, 1 was found to 
have radiographic evidence of CUC (case. 4). Eighteen months later, when she had a recur-
rence of PG, bowel screening showed no evidence of CUC. On follow-up two years later, 
she remained asymptomatic. The remaining 14 patients had completely normal gastrointes-
tinal tracts on screening. Two patients with bowel symptoms at, or soon after the develop-
ment of PG (cases 1,5), were found to have IBD on barium studies. One other patient, 
known to have Crohn's disease of longstanding, was asymptomatic for bowel disease (radio-
logically and clinically normal) at the time she developed PG (case 2). 
Callen, too, recommends routine studies of the gastro-intestinal tract, but this recommenda-
tion does not appear to be based on sound data7. Judging from the Perry, Mayo clinic an:d 
GSH series, it seems hard to justify routine gastro-intestinal radiography in patients without 
signs or symptoms of bowel disease. 
THERAPY 
Evaluation of therapy is very difficult in a disorder that runs an unpredictable course and is 
subject to remissions and exacerbations. This problem is compounded in PG by the lack of 
uniformity in approach to treatment and the many drug regimens recommended. In the 
GSH series, systemic corticosteroid therapy was the favoured treatment, either alone or in 
combination with other agents in 38 patients (84.4% ). Favourable responses occured in all 
(complete remission was obtained in 27, partial healing in the remainder). In the GSH 
series, the starting dose of oral prednisone (or maintenance dose after pulse therapy), was 
1mglkglday, in all cases. Pulse therapy (1G methyl prednisolone intravenously daily for 3 
days) was administered in 5 patients ( 11.1%) in the GSH series. In 4, it was administered 
specifically for the cutaneous disease (cases 20, 31, 33, 40) while in the remaining patient, 
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the major indication was for the associated disease, rheumatoid vasculitis (case 17) with fa-
vourable response being obtained for both the systemic and cutaneous disorders. Where 
the pulse was given for the cutaneous disease alone, 3 obtained remission (cases 20, 31, 40) 
while the fourth (case 33) had only partial healing at the time of writing. Pulse therapy was 
first recommended for PG in 1982111 (3 patients were treated). The same group of authors 
subsequently treated 8 patients (6 successfully) with this form oftreatment78• A much 
larger group of patients should be studied before the efficacy of pulse therapy in PG can be 
evaluated. 
Steroid-induced complications were recorded in 18 patients in this study and included oste-
oporosis, diabetes mellitus, hypertension, moon facies, striae, and truncal obesity (refer to 
table 4 for individual patients). Four patients developed serious infections while on corticos-
teroid therapy (pulmonary tuberculosis in 3 - cases 26, 44, 45 - and systemic nocardiosis in 
the fourth (case 27). One patient sustained a fracture of the neck of femur (case 21) and an-
other (case 33) suffered bilateral fractures of his achilles tendons while on oral prednisone 
forPG. 
Side-effects of adjuvants used in the GSH series included bronze pigmentation due to clofa-
zamine (in two patients, cases 27 and 29), renal impairment due to cyclosporin, neutro-
paenia due to cyclophosphamide and azathioprine in case 27 and intolerable headache on 
sulfasalazine in two (cases 31 and 40). 
In the earliest of the published series, Brunsting employed general measures in the form of 
blood transfusions, adequate diet, tanning via a quartz mercury-vapour lamp, local 
measures aimed at reducing inflammation and oral medication in the form of potassium 
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iodide and arsenic, all of which met with varied responses1. The impression was that the dis-
ease course was in no way influenced one way or the other by the measures employed. 
In the GSH study, one patient (case 16) healed after a protracted course of topical steroid 
ointment and local measures (presumably, systemic therapy was not considered as the ul-
cers were relatively small and limited to the legs). 
In a 1957 study, Brunsting and Perry reported "good" responses in. 9 of 13 patients ( 69.2%) 
treated with salicylazo-sulfapyridine (sulfasalazine ). This included 3 patients without CUC. 
However, details of extent of cutaneous disease, length of treatment and exact dosage for 
maintenance, time taken to healing etc. are lacking from this report2. Subsequently, sulfapy-
ridine and sulfone-type drugs were found to be effective in PG 108. 
In the GSH study, sulfazalazine was used as an adjuvant with corticosteroids in 12 patients 
and sulfapyridine in 1. Neither of these drugs were chosen as first line of treatment in any of 
the patients. In the GSH series, diaminodipheny1sulfone (dapsone) was chosen as first-line 
in one patient (case 36) with good effect. Despite this, it was not the drug of choice in sub-
sequent cases of PG seen at GSH. Since the reports of Perry (1957) and Lorinez (1962),the 
sulphonamides appear to have been relegated to role of adjuvants after corticosteroids 
were shown to be unquestionably effective in PG. In the GSH series, the addition of sulfasa-
lazine and sulfapyridine appeared not to have any influence on the overall pattern of PG in 
the patients where it was prescribed. 
Adrenal steroids have been administered systemically for <)ver 32 years110. Perry in his re-
port of 62 patients with PG in 1969, stated that the trend of therapy at that time was toward 
the use of sulfapyridine, either alone or in combination with corticosteroids. He found sys-
temic corticosteroids particularly valuable when the PG was fulminating and destructive3. 
This has certainly been the trend in the GSH series, where the majority of patients re-
sponded favourably to corticosteroids. 
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Clofazamine has been reported as being effective in PG113-115 and was the drug of choice in. 
1 patient (case 29) in the GSH series, but response was poor (healing occurred only after 
corticosteroid was added.) Clofazamine was continued together with oral prednisone in this 
patient but appeared not to influence the overall course of PG. Other agents that were tried 
in combination with corticosteroids in the GSH series included minocycline, azathioprine, 
cyclosporin and thalidomide, all of which appeared to have dubious effects on the overall 
course of PG. Many factors such as inadequate dosage, length of trial period, lack of careful 
documentation may have led to this negative impression of adjuvants and their efficacy will 
thus have to be established with a more controlled study of corticosteroids with and without 
adjuvants, over a long period, to resolve this issue. Agents other than corticosteroids (given 
the serious side effects of these agents even at relatively low-dosage levels) are always being 
h C . b . d. d f d . d. 119-122 139 I soug t. ytotoxtcs may e m tcate or severe an extensive tsease ' . ntravenous 
cyclophosphamide and methylprednisolone, as recommended for rheumatoid vasculitis by 
Scott and Bacon140, may be a wise choice in the light of increasing evidence that PG may be 
a vasculitic process and given the debilitating nature and poor prognosis of extensiv~ PG. 
CHAPTER SIX 
SUMMARY 
Forty-five patients were diagnosed as suffering from pyoderma gangrenosum (PG) at 
Groote Schuur hospital over a twenty-year period. 
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The majority of patients appeared to follow the acute, rapidly progressive pattern of the dis-
ease, while a small number apparently followed the more indolent, slowly progressive 
course described for some cases of PG. 
The age, sex, morphology of the skin lesions, presence or absence of an associated disease 
and presence or absence of vasculitis in tissue taken from the cutaneous lesions, appeared 
to have no influence on response to therapy or overall prognosis of this condition. The ex-
tent of cutaneous involvement, however, did appear to adversely affect the course of the dis-
ease when large areas were involved. 
Corticosteroid therapy was the mainstay in the majority of patients and although it ap-
peared to result in a favourable response in many, its influence was largely unpredictable. 
The role of adjuvants was dubious but lack of detailed case notes may have led to this nega-
tive conclusion. 
The successful use of the Scott and Bacon protocol 140 in 2 patients in the GSH series 
(cases 17 ,30) for underlying rheumatoid vasculitis and systemic leucocytoclastic vasculitis, 
respectively, was noted to result in the resolution of th~ir PG lesions as well. 
This study highlighted some of the problem areas in PG, namely, establishment of clinical 
patterns, relationship of associated disease (when present) to the cutaneous disorder; role 
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of adjuvants and pulse therapy in management; role of vasculitis in pathogenesis of PG and 
the unpredictability of responses to therapy. Another aspect highlighted was the importance 
of detailed case notes in poorly understood disorders like PG. This would allow for valid 
conclusions to be drawn on various aspects of the disease in a retrospective study of this na-
ture. 
The results of this study have led to recommendations (that include a format for the diag-
nostic evaluation, follow-up and therapeutic suggestions in patients with suspected PG) 
which hopefully, will lead to improved management of these patients in the future. 
The GSH experience has confirmed that PG is an uncolinnon condition, but nevertheless a 
crippling, distressing disorder for the individual patient while for the attending physician it 
remains a diagnostic and therapeutic dilemma. 
CHAPTER SEVEN 
RECOMMENDATIONS 
PATIENT MANAGEMENT 
Based on the literature review and this study of GSH patients, the following approach to 
the patient with PG is recommended : 
FIRST VISIT (DIAGNOSTIC EVALUATION) 
NAME, DATE OF BIRTH, SEX. 
HISTORY 
Age at onset 
Clinical appearance at onset 
Time for development of established ulcer 
Precipitating trauma 
Presence of pain (mild, moderate, severe) 
Joint pain 
Associated disease 
EXAMINATION 
Number, size, site of active lesions. Extent of scars of previous ulcers. (Diagram). 
Routine physical examination (to include signs of associated disease activity if present; de-
tail of arthritis if present). 
Sideroom: Haemoglobin; urine for protein, blood, glucose; stool for occult blood. 
ASSESSMENT 
(1) Probable PG 
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(2) Classic PG 
PLAN 
LAB ORA TORY INVESTIGATIONS 
Chest X-ray 
Full blood count 
Serum biochemistry (including renal, liver function tests and blood glucose level) 
Skin biopsy (from peripheral zone of erythema and/or early vesicopustule if present) for 
histology and cultures (bacterial, fungal, viral) 
Serum protein electrophoresis and immunoelectrophoresis. 
Radiological studies of gastro-intestinal tract (only if indicated from history and/or physical 
examination). 
Appropriate serological tests to assess degree of activity of associated disease if present. 
THERAPY 
PROBABLEPG 
Local care and analgesia until PG confirmed. 
CLASSIC PG (see flow chart) 
MANAGEMENT OF ASSOCIATED DISEASE (if present) 
PROGRESS CHART 
(Two weekly visits for first six weeks, four weekly thereafter). 
HISTORY 
Pain in lesions 
Size of lesions 
New lesions 
Activity of associated disease (if present). 
EXAMINATION 
Size, site, number of active lesions (diagram). 
Healing 
Extens.ion 
Side effects of corticosteroids/other medication 
Activity of associated disease (if present) 
NO/INCOMPLETE/COMPLETE 
YES/NO 
Results of laboratory investigations (highlight abnormalities) 
ASSESSMENT: 
PLAN 
THERAPY (see flow chmt) 
MANAGEMENT OF ASSOCIATED DISEASE (ifpreesent) 
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THERAPY FLOW CHART 
Rapidly Progressive 
(limited) Slowly Progressive Severe. extensive PG 
df. Pre n1sone l 
1mg/lcg/day Hospitalise for IV 
/ X2/52 '\ cyclophosphamide and 
methylprednisolone 
Good Response Poor Response (Scott & Bacon) 140 
J 
Continue at this 
dose until 
healed then 
taper to 
maintenance 
I . Good Response - Continue on 
Hospitalise ./ maintenance 
for pulse /"" prednisone 
therapy ~ 
Repeat pulse 
Poor Response- weekly X 2 
~ ".. 
Good Response Poor Response 
maintenance! prednisone Consider sbo~vBacon 
Protocol 
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SUGGESTED RESEARCH PROJECTS 
(that might be done in Cape Town) 
(a) CLEAR DOCUMENTATION OF CLINICALPATTERNS OF PG prior to and after 
commencing therapy (may offer better prognostic evaluation than in the past). This should 
include size, number, site, extent of cutaneous involvement, pattern of presentation and pro-
gression, response to standardized therapy, (including time to healing), activity of associ-
ated disease and its influence (if any) on the cutaneous disease. 
(b) PATTERNS OF POLY ARTHRmS IN PG (to see whether the unique pattern of arth-
ritis elicited by Holt et al is present in patients with PG seen in the Western Cape )56. 
(c) To determine the VALUE OF CYTOTOXIC$ alone or as adjuvants in recalcitrant cases 
ofPG. 
(d) To determine the incidence of MONOCLONAL GAMMOPATHIES in PG in Cape 
Town, using immunoelectrophoresis in all cases. 
(e) A careful CLINICO-HISTOPATHOLOGICAL STUDY (with particular care taken that 
biopsies are taken from early vesicopustules and/or the peripheral erythematous zone of ad-
vancing lesions) to establish the role of vasculitis in PG. 
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APPENDIX 
CASE REPORTS 
INFLAMMATORY BOWEL DISEASE 
CASE 1 : MRS G.S. (Date of birth 04/12/1939) 
April1975 
September 1975 
Sep 1975- Nov '81 
November 1981 
August 1982 
February 1983 
January 1984 
February 1984 
March 1984 
Severe oro-pharyngeal ulceration. Histology: Chronic inflammatory 
cells. Diagnosis: "limited" Wegener's granulomatosis." (In view of se-
verity despite lack of histologic proof). Treatment : Prednisone 
40mg/daily. Healed promptly. 
Off prednisone. Oral ulcers recurred together with a vesiculo-pustu-
lar rash. Histology : no vasculitis. . 
Diagnosis: Wegener's granulomatosis. Treatment: Oral prednisone. 
Skin and oral lesions healed. 
Repeated episodes of oral ulceration and vesica-pustular rash oc-
curred when prednisone was tapered below 20mg/daily. 
Watery diarrhoea but barium studies normal. 
Pyoderma gangrenosum of left calf. Recurrence of oral ulcers (Still 
regarded as limited Wegener's granulomatosis, no vasculitis, normal 
chest X-ray) Treatment: Prednisone. Complete resolution. 
Melaena. Barium studies- "Crohn's disease of long standing". Treat-
ment : Maintenance prednisone increased. Course: Symptoms re-
solved. 
Leg PG, oral ulcers, diarrhoea recurred. (Prednisone had been 
stopped). At this stage, markedly cushingoid, osteoporotic, hyper-
tensive, myopathic. Uvula completely destroyed. Treatment : Predni-
sone 40mg/daily. 6 Mercaptopurine (6MP) 50mg/daily. 
Skin and oral ulcers healed. Prednisone tapered to 20mg/daily. 
Slight flare of oral ulcers. 6MP increased to 100mg/daily. 
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May 1986 For more than two years, had required frequent increases of oral 
prednisone from 15mg/daily to 40mg/daily for 2 to 3 week periods at 
a time to control oral ulcers and bowel symptoms. (Had no further 
cutaneous PG since January, 1984). 
June 1986 Prolonged total parenteral nutrition (12 weeks) substituted for 
chronic corticosteroid therapy Response : Good. 
September 1986 Stable off all systemic treatment. 
October 1986 Acute arthritis of left ankle. Treatment : Sulfasalazine 3G/daily. 
Good response. 
Nov 86- May 88 Remission. No systemic treatment 
June 1988 Severe flare of oral ulceration. Bowel asymplomatic. Treatment : 6 
Mercaptopurine (6MP) 75mg/daily. Ulcers resolved completely. 
April1989 Remission maintained on 6MP 75mg/daily. 
May 1989 Stopped taking 6MP. 
September 1990 Established that she has maintained this last remission. Has had an 
occassional flare of oral ulceration and bowel disease. (Both usually 
mild, clearing spontaneously after a day or two) No further PG. 
COMMENT This is probably a case of oral PG, in which case the oral lesions preceded the 
developme'!t of sk{n l~sions _by several years (unlike the reported c'f!J~18where the oralleswns coznetded wlth the development of cutaneous PG) · . 
CASE 2: MISS L.J. (Date of birth 13/07/1966) 
July 1981 
August 1981 
October 1981 
June 1982 
June 82- Aug 86 
Severe Crohn's disease diagnosed. (Terminal ileum, colon, rectum 
involved). Treatment : Oral prednisone 40mg/daily. Total parenteral 
nutrition. Predsol enemas. 
Defunctioning colostomy performed. (Due to failure of above treat-
ment to control symptoms). Treatment: Post-operatively- lOOmg hy-
drocortisone down ileostoma I daily. 
6 Mercaptopurine ( 6MP) SOmg/daily added. 
Symptoms persisted - total colectomy performed. Rectum left in situ. 
6MP stopped. Treatment: Post-operatively- Prednisone 50mg/daily. 
Stable. Gradually weaned off oral corticosteroids altogether. 
September 1986 
September 1986 
January 1987 
March 1987 
May 1987 
December 1988 
March 1989 
August 1989 
October 1989 
December 1989 
January 1990 
February 1990 
April1990 
June 1990 
September 1990 
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Acute, non-erosive arthritis of left knee. (Three weeks after stopping 
prednisone). Treatment: Non-steroidal anti-inflammatory (diclophe-
nac) - settled. 
One week after acute arthritis, developed peristomal "abscess" and 
two weeks thereafter, perineal ulceration. Treatment : Antibiotics, 
Predsol enemas. 
Pyoderma gangrenosum of peristomal and perineal regions diag-
nosed. No evidence of bowel activity on barium studies. Treatment: 
Prednisone 60mgldaily. 6 MP SOmgldaily. 
PG healed. Bowel asymptomatic. 
Weaned off prednisone but still on 6MP SOmgldaily. 
Remission. 6MP stopped. 
Acute arthritis left knee. Treatment: Diclophenac. 
Recurrence of perineal ulceration. Bowel inactive. (clinically and 
radiologically). Treatment: Prednisone 80mgldaily. Dramatic reduc-
tion in pain but healing of ulcers was slower. 
Noted that: "large anal cleft ulcer persists." Sulfasalazine 3G/daily 
added to regimen. 
Prednisone tapered to 20mgldaily. Perineal ulceration persisted. 
Bowel inactive. Proctectomy with resection of caecum and terminal 
ileum performed. Post-op Treatment: Prednisone 20mgldaily. Sulfa-
salazine 3G/daily. 
"Ongoing perineal sepsis." Patient weaned off steroids. 
Deterioration of perineal ulceration. Diagnosis : PG. Treatment: 
Prednisone 125mgldaily. Sulfasalazine 3G/daily. 
Active ulceration absent. Large cavity occupied the perineum. Treat-
ment : Prednisone SOmgldaily. Sulfasalazine 3G/daily. 
Noted that perineal wound had decreased in depth but adjacent skin 
showed little evidence of healing. Prednisone was considered to have 
little effect and patient was advised to wean herself off completely. 
Peristomal "excoriation" noted. Perineal wound was thought to be 
smaller but margins were tender. Treatment : Sulfasalazine 3G/daily. 
Off prednisone. 
COMMENT This patient illustrates the diagnostic and therapeutic dilemmas faced by the 
attending physicians of the patient with Crohn 's disease who presents with peri-
neal ulceration. Although a sarcoid-like histology may help to differentiate 
perineal Crohn 's from perineal PG, its absence does not necessarily preclude a 
diagnosis of regional ileitis. Such patients, either way, may benefit from a 
course of pulse methylprednisolone. 
CASE 3 : MISS M.I. (Date of birth 08/12/1959) 
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1980 Diagnosis : Crohn's disease. Treatment : Oral corticosteroids Course 
:Stable. 
June 1985 Pyoderma gangrenosum. (Slowly progressive superficial ulcers of 
both lower legs). Histology : (early vesicopustule) Leucocytoclastic 
vasculitis of upper dermal vessels. Bowel in remission. Treatment : 
Prednisone 60mg/daily. Dapsone lOOmg/daily. Course : Completely 
healed over 16 weeks. 
Nov 1985- Jan 1986 Limited recurrences occurred at any attempt to reduce prednisone 
below 20mg/daily. 
February 1986 Sulfasalazine 4G/daily substituted for dapsone. Made no difference. 
Still unable to achieve control below prednisone 20mg/daily. 
January 1987 6MP lOOmg/daily substituted for sulfasalazine. Still unable to reduce 
prednisone below 20mg/daily without a flare. 
July 1987 Crohn's disease flared. Treatment : Prednisone increased from 
20mg/daily to 40mg/daily. 6MP continued. Course: Completely 
healed after 10 weeks. Bowel remitted. 
November 1987 Weaned off oral prednisone with no flare of skin or bowel. 6MP 
stopped. 
November 1987 No further episodes of PG. 
November 1990 Has continued to have intermittent flares of Crohn's disease that are 
readily controlled on systemic therapy (usually corticosteroid). 
COMMENT No clearcut relationship between bowel activity and skin ulceration could be 
demonstrated in this patient. Although her overall course was one of slow pro-
gression, this was while on treatment. The fact that she rapidly deteriorated 
with lowering of the prednisone below 20mg/daily indicates that she in fact 
falls into the acute, rapidly progressive group of PG. 
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. CASE 4 : MRS M.I. (Date of birth 18/01/1946) 
July 1987 
August 1987 
October 1987 
January 1988 
January 1989 
Pyoderma gangrenosum of left scapular region (figure 1). Rapidly 
progressive. No bowel symptoms but barium studies (done as part of 
screening tests in PG) revealed evidence of ulcerative colitis. Treat-
ment : Prednisone 60mg/daily. Sulfasalazine 3G/daily. (In view of 
bowel findings). 
Bilateral salpingo-oophorectomy. (Under corticosteroid cover)-
large ovarian mucinous cyst adenoma removed. Laparotomy site 
healed with no problem. 
PG healed. Patient weaned herself off corticosteroids and stopped 
taking sulfasalazine. 
PG (1 x 2cm ulcer) developed on right shin. Bowel remained asymp-
tomatic. Treatment :Topical medium potency steroid ointment. 
Course : Healed over 3 weeks. 
Recurrence of PG overlying right ankle. Bowel asymptomatic. (Re-
peat barium studies- normal). Treatment: Prednisone 60mg/daily. 
Sulfasalazine 3G/daily (Sulfasalazine prescribed despite normal 
bowel studies because of previous rapid response). Course : Com-
pletely healed in 3 weeks. 
September 1989 Remained healed. Off systemic treatment. Patient has emigrated. No 
further follow-up available. 
COMMENT Asymptomatic 1'!flammatory bowel disease has been reported to occur in pa-
tients with PG. ' . The IBD changes are detected radiologically, when barium 
studies are done as part of the routine work-up of "idiopathic PG". In this pa-
tient, all evidence of IBD disappeared 18 months later. She remained asympto-
matic with regard to bowel symptoms throughout her course. 
CASE 5: MRS N.S. (Date of birth 01/01/1940) I 
May 1989 
September 1990 
Pyoderma gangrenosum of head and neck (figure 4 ). Rapidly pro-
gressive ulcerative lesion. (atypical PG) Ulcerative colitis diagnosed 
at the same time. (Watery diarrhoea for 4 months prior to ulcera-
tion). Treatment: Oral prednisone 60mg/daily x 1 week, failed to 
halt ulcerative process. Given pulse Methylprednisolone 1G 
IVI/daily~ Split skin graft done under corticosteroid cover. Donor 
site healed with no problem. Course: 100% take of skin graft. Bowel 
symptoms resolved. 
Established that PG and ulcerative colitis have remained in re-
mission on Sulfasalazine 3G/daily and clofazamine 100mg/daily. (Pa-
tient had been successfully weaned off corticosteroids several 
months previously). 
COMMENT 
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This patient had rapidly progressive ulceration of right side of neck that did 
not have the characteristic clinical appearance of PG, but resolved on adequ-
ate dosg of corticosteroids. This patient best fits the description given by An-
derso!l w~o wined the term "m_alignant pyoderma". This term is now felt to 
be mzsleadmg and the alternatzve, ''pyoderma gangrenosum of the head and 
neck" is thought to be more acceptable. Rapid recognition of pyoderma gan-
grenosum when it occurs at atypical sites is important because of the poten-
tially destructive nature of this disorder and because the disease may be more 
responsive to therapy in the early stages. In suspected cases, high-dose corticos-
teroid therapy should be instituted as soon as tissue has been obtained for ap-
propriate microbiologic and histopathologic studies. 
CASE 6 : MRS L. N. (Date of birth 05/12/1949) 
February 1984 
November 1985 
July 1989 
March 1990 
May 1990 
Diagnosis: Crohn's disease. Treatment: Intermittent course of oral 
prednisone with good effect. 
Diagnosis: Ankylosing spondylitis. Treatment: Non-steroidal anti-in-
flammatory drugs. Course: slow progression. 
Pyoderma gangrenosum of left shin. (Following trauma). Bowel 
asymptomatic. Treatment : Prednisone 40mg/daily. Sulfasalazine 
4G/daily. Course: Healed rapidly over six weeks. (Prednisone 
tapered to zero over 8 weeks). 
Crohn's disease flared. Rapid recurrence of PG at the same site. 
Treatment: Prednisone 60mg/daily. Course: Rapid resolution of 
bowel symptoms associated with complete healing of pyoderma gan-
grenosum in two weeks. 
Failed to take prednisone for one week. Acute and rapid deteriora-
tion of both bowel and PG (at the same rate). Again, prompt healing 
with re-institution of prednisone therapy. 
September 1990 Remission on Prednisone (bowel and skin). 
COMMENT This patient's PG was clearly responsive to corticosteroids. She again demon-
strates that occurrence of PG is not always associated with IBD activity. Sulfa-
salazine was not added on the second relapse of PG. It remains to be seen if 
remission is sustained when the prednisone is tapered to zero. 
CASE 7: MRS R.H. (Date of birth 21/05/1927) 
1962 
1969 
April1970 
July 1970 
July 1970 
May 1974 
May 1978 
3rd degree vaginal tear while delivering twins. Failed to heal com-
pletely. 
Recto-vaginal fistula. 
Defunctioning colostomy prior to repair of recto-vaginal fistula. 
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Following surgery, discharging sinuses developed at colostomy scar 
(which had been closed subsequently) and at site of recto-vaginal fis-
tula repair. Diagnosis : ? Crohn's disease. Barium studies : "extensive 
diverticulosis". Treatment: Conservative. 
Sinuses persisted and extended. 
New sinus developed spontaneously in left iliac fossa. Non-function-
ing kidney (chronic glomerulo-nephritis). Diagnosis : ? Crohn's dis-
ease. Barium studies repeated : again reported as "extensive 
diverticulosis." Treatment : Sinus tracts laid open. Left nephrectomy. 
Course : Stormy. Faecal peritonitis. Development of multiple fistu-
lae at sites of drain insertions. 
After a protracted course, requiring many hospital admissions to 
manage the multiple anterior abdominal wall fistulae, a TOTAL CO-
LECTOMY was performed. Histology of the colon revealed unequi-
vocal Crohn's disease. 
May 1978 - Jul1982 Stable on conservative therapy (mainly stoma care). 
August 1982 
April1983 
March 1985 
Developed pyoderma gangrenosum of parastomal region and left 
lower leg. Crohn's in remission at the time. Treatment : Prednisone 
40mgldaily. Course : Healed completely over a period of 20 weeks 
on tapering doses of prednisone. 
Healed PG. Off prednisone. 
Small bowel enema- no Crohn's disease. 
September 1990 Patient alive and well, on no systemic treatment. 
COMMENT Patient developed pyoderma gangrenosum 4 years after total colectomy for 
Crohn 's disease and at a time when Crohn 's disease was not demonstrated in 
the small bowel. PG should he considered in patie~ffJ with previous IBD, even 
if apparently cured, when skin ulceration develops . 
CASE 8 : MRS C. C. (Date of birth 02/04/1958) 
October 1987 
December 1987 
April1988 
July 1988 
August 1988 
April1989 
July 1989 
July 1989 
Total Crohn's colitis. Treatment : Oral prednisone. 6 Mercapto-
purine. Response good. 
Right transverse colectomy performed. 
Treatment: post-operatively- prednisone 60mgldaily. 
Prednisone tapered then stopped over 8 weeks. 
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Acute arthritis left knee, left hip, left shoulder. Flare of Crohn's 
colitis. PARASTOMALPYODERMAGANGRENOSUM. Treat-
ment : Prednisone 60mgldaily. 6MP 75mgl daily. Response slow but 
favourable. 
Prednisone tapered more cautiously this time. PG healed. Arthritis 
and Crohn's remitted on prednisone 20mgldaily and 6MP 75mgldaily. 
Prednisone down to 5mgldaily. 6MP stopped. (neutropaenia) 
Stable 
Mar 1990- Apr 1990 Perianal "abscess". Active Crohn's of rectum and distal sigmoid. 
Treatment: Prednisone 60mgldaily. 
July 1990 Left hemicolectomy and proctectomy. Treatment: (post-operatively) 
- nil systemic. 
August 1990 Last recorded outpatient visit- well. No parastomal, perineal or skin 
lesions. Bowel in remission. 
COMMENT Pyoderma gangrenosum developed after transverse colectomy. Resolved on 
oral prednisone therapy. The perianal "abscess" may well have been a flare of 
PG but this was not confirmed. It is interesting to note, that after further radi-
cal surgery, followed by no systemic therapy, patient appears to have gone into 
remission, with regard to both the Crohn 's disease and perineal problem. 
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CASE 9: MR A.N. (Date of birth 04/03/1943) 
1970 
1972 
1976 
1976-1980 
June 1980 
August 1980 
Chrome ulcerative colitis (CUC) diagnosed. 
Total colectomy performed (left with permanent ileostomy). 
Developed chronic active hepatitis (CAH) 
CUC and CAH controlled on oral prednisone. 
Developed severe oral ulceration (described as "hanging cascade of 
pus" obscurring the uvula, with suppurative ulcers of tongue and pal-
ate). Associated with oral ulcers are PYODERMA GANGRENO-
SUM of scrotum, left leg and left ear. Bowel and liver in remission. 
Treatment: Prednisone 40mg/daily. 
Oral and skin lesions healed. 
September 1990 No further oral or skin lesions. Bowel has remained in remission, but 
chronic active hepatitis activity has required the addition of azathio-
prine. Currently stable on prednisone 25mg/alternate days and aza-
thioprine lOOmg/daily. 
COMMENT This patient developed oral and cutaneous lesions when the bowel and liver 
were assessed as being in remission. The differential diagnosis of the oral ul-
cers in this setting would include pyoderma gangrenosum, major apthous ul-
cers and pyostomatitis vegetans. PG is favoured as the latter two nearly always 
accompany severe flares of the bowel disease. Also, the presence of PG on the 
skin elsewhere, supporls the diagnosis of oral PG. However, as in case 1, all3 
oral lesions serve as markers of IBD, the treatment of which is expected to 
lead to resolution of the mucosal lesions as well. Distinguishing one from the 
other may be very difficult clinically. 
CASE 10 : MR A. G. (Date of birth 21/11/1956) 
1965 
September 1974 
August 1975 
Chronic ulcerative colitis diagnosed. Treatment: Prednisone. Sulfasa-
lazine. Predsol enemas. Course : Fluctuating. 
Proctocolectomy. Treatment: (post-operative) Predsol enemas. Sul-
fasalzine. 
Pyoderma gangrenosum of lower legs and perineum·. (Bowel in re-
mission). Treatment : Methylprednisolone 64mg/daily 
November 1975 
December 1975 
April 1978 
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Complete healing of leg PG. Partial healing of perineal PG. Methyl-
prednisolone tapered. 
Acute deterioration of perineal ulceration. Recurrence of leg PG. 
Treatment : Methylprednisolone 64mg/daily. Split skin graft of peri-
neal defect (failed). Continued oral methylprednisolone. Eventually, 
(March 1978) healing of leg and perineal PG occurred. Prednisone 
stopped. 
Healed perineal defect was closed with a gracilis-myocutaneous flap. 
Good healing immediatedly post-operatively. Off systemic corticoste-
roids at the time. 
May 1978 - Apr 1979 Recurrent small areas of breakdown and ulceration which healed on 
conservative treatment. 
April1979- Nov 1990 Apart from occasional bouts of perineal sepsis, has remained well. 
Bowel and skin have been in remission (off systemic treatment) since 
April 1979. Ileostomy functioning well. 
CASE 11: MRS P.C. (Date of birth 07/07/1935) 
1972 Watery diarrhoea for 3 months. Diagnosis:? Inflammatory bowel 
disease. Barium studies: NORMAL bowel. Treatment : Anti-diar-
rhoeal drugs. Course : Intermittent bouts of diarrhoea that re-
sponded to anti-diarrhoeal medication. 
October 1978 Pyoderma gangrenosum of leg (single lesion). Bowel asymptomatic. 
Treatment: Methylprednisolone (dose unknown) x 1 week. Course: 
"Little improvement". 
December 1978 Referred GSH re profus~ watery diarrhoea. Barium studies repeated 
:unequivocal Crohn's disease. PG of right leg had extended. Treat-
ment: Prednisone 60mg/daily. Course: Ulcer started to heal slowly 
over next 3 weeks. Bowel symptoms also resolved. 
January 1979 Patient was referred back to her practitioner in another town and 
was lost to follow-up. 
COMMENT The appearance of PG in patients with IBD may be a predictor offlaring 
bowel disease, as was demonstrated in this patient. 
CASE 12: MISS R.N. (Date of birth 14/02/1961) 
November 1976 Diagnosis: Chronic ulcerative colitis. Course : Unstable 
November 1978 
August 1981 
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Panproctocolectorny. Histology- Crohn's disease. 
Parastomal PG. Crohn's disease active. Patient refused oral corticos-
teroids. Course :Fluctuated with intermittent healing and break-
down around stomal area. 
September 1990 Ongoing problems of parastornal ulceration, arthralgias, discharging 
vesico-vaginal fistula but still refuses to take oral corticosteroid or 
immunosuppressive therapy. 
COMMENT This patient's PG has paralled the underlying disease activity. She remains 
chronically unwell hut prefers homeopathic medication. She will probably con-
tinue in this fashion until the disease process spontaneously "hu~ itself out". 
It is possible that early reports of the association of PG with CUC included 
patients in whom the correct diagnosis was really Crohn 's disease as this pa-
tient demonstrated. 
CASE 13: MRS E.W. (Date of birth 14/07!1953) 
April1985 
May 1985 
December 1985 
March 1986 
October 1986 
October 1990 
COMMENT 
ARTHRITIS 
Diagnosis: Chronic ulcerative colitis. Course: Severe disease. 
Total colectomy. Histology : Crohn's disease. 
Extensive parastomal and laparotomy scar ulceration. Diagnosis : 
Pyoderma gangrenosurn. Treatment : Oral corticosteroids. Total par-
enteral nutrition. Response : Poor. 
Ileostomy resited to left iliac fossa. Active IBD. Oral prednisone con-
tinued. 
Completely healed PG. Bowel in remission. 
Stable. On no systemic therapy. 
Healing of recalcitrant parastomal PG C)JflY after resiting the stoma, as oc-
curred in this patient, is well recognizea . 
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CASE 14: MRS G.S. (Date of birth 24/03/1930) 
1972 Sero-positive rheumatoid arthritis (RA). Treatment: Non-steroidal 
anti-inflammatory drugs. (NSAID) 
1979-1980 Treatment : Gold. 
July 1982 Pyoderma gangrenosum of left lower leg diagnosed (following an in-
jury). Rheumatoid arthritis in remission on Piroxicam (NSAID). 
Treatment: Methylprednisolone 48mg/daily. Dapsone lOOmg/daily. 
Split skin graft ( 60% take). 
August 1983 PG healed. Weaned off corticosteroid. Dapsone stopped. 
January 1984 Well. No PG. Rheumatoid arthritis stable on indocid suppository, 1 
nocte. No further follow-up available. 
COMMENT V asculitic skin ulcers in rheumatoid ~{fhritis may be difficult to differentiate 
from the characteristic lesions of PG . Even the absence of vasculitis on skin 
histology does not preclude a diagnosis of rheumatoid vasculitis as this may be 
due to sampling error. Unfortunately documentation of a biopsy having been 
done is lacking from this patient :5 notes and the diagnosis appears to have 
been made on morphological grounds. 
CASE IS: MRS S.S. (Date of birth 17/02/1928) 
1966 
August 1975 
October 1975 
November 1975 
May 1989 
October 1989 
Seronegative rheumatoid arthritis. Treatment : NSAID. 
Pyoderma gangrenosum of right lateral thigh at site of surgical scar 
(figure 16) and dorsum of right foot. Rheumatoid arthritis (RA) in 
remission. Treatment: Methylprednisolone 48mg/daily. 
PG healed. 
Weaned off corticosteroids. 
Returned ( 13 and a half years later) with recurrence of PG in the 
right iliac fossa area. RA in remission. Treatment : Prednisone 
60mg/daily. Sulfasalazine 4G/daily. (for steroid-sparing and thera-
peutic effects). " 
PG healed. Prednisone tapered gradually. Sulfasalzine continued. 
Failed to come for further follow-up. 
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September 1990 Reliably established that patient is completely well off all systemic 
treatment. 
COMMENT Two limited courses of PG, 14 years apart, with prompt and complete healing 
on oral corticosteroid therapy on both occasions. On the first occasion, pyoder-
ma gangrenosum occurred 2 weeks after hip joint surgery at the site of a drain-
ing sinus. The second time, onset was spontaneous. On both occasions, the 
RA was inactive. A confident clinical diagnosis of PG was made. Skin biopsies 
were not done. · 
CASE 16: MRS S.A. (Date of birth 10/11/1977) 
1959 
1977 
February 1980 
September 1990 
COMMENT 
Sero-negative rheumatoid arthritis. Treatment: Non-steroidal anti-
inflammatories. Course : Slowly progressive but adequately control-
led on non-steroidal anti-inflammatories alone. 
2 x lcm ulcer of pyoderma gangrenosum developed on left lower leg. 
Slowly progressive x 3 months. Several more ulcers over both legs in 
the months following. Treatment: Fluorinated corticosteroid oint-
ment. Course : Healed slowly over a period of 24 weeks. 
Pyoderma gangrenosum recurred on left lower calf and dorsum of 
right foot. (Ulcers less than 3cm in size). Slowly progressive. Treat-
ment : Fluorinated topical steroid. Course : Healed over a period of 
9 months. 
No further episodes of PG. Still attending arthritis clinic regularly. 
Stable on NSAID's. 
This patient developed small, slowly progressive pyoderma gangrenosum ul-
cers that healed with topical therapy alone. At the time her rheumatoid symp-
toms were controlled on non-steroidal anti-inflammatory drugs. FavouraJ?lros 
responses in PG to topical therapy is well documented but is uncommon ' . 
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CASE 17: MRS P.M. (Date of birth 23/03/1921) 
1976 55 years old. Sero-positive rheumatoid arthritis. Treatment: 
NSAID's 
October 1984 Mononeuritis multiplex (with presumed cerebral, pulmonary and cu-
taneous vasculitis) Associated with typical lesions of pyoderma gan-
grenosum of sacrum, right calf, left 5th digit. Musculo-skeletal 
system : no objective art~rit~40Treatment : Pulse Methylpredniso- , lone and cyclophosphamide · . 
July 1985 Slow recovery. PG healed. Treatment : Prednisone 20mg/daily. 
(Course complicated by development of diabetes mellitus- control-
led on oral agents). 
January 1987 Last recorded visit to GSH. Stable on cyclophosphamide 50mg/daily 
(which had been introduced in September 1985 after PG healed). No 
further follow-up available. Current status unknown. 
COMMENT This patient's skin lesions were described as "livedo-reticularis type over feet 
and legs, nail fold infarcts of left big toe, numerous vasculitic lesions of face 
and large ulcers of sacrum, right calf and left fifth digit." The large ulcers were 
diagnosed as PG by the dermatologists but unforlunately no record of these or 
the "vasculitic" lesions having been biopsied exists. Under these circumstances 
distinguishing PG from vasculitic ulcers may be very difficult. One can only as-
sume that the lesions diagnosed as PG were clinically compelling. 
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LEUKAEMIC AND PRE-LEUKAEMIC CONDITIONS 
CASE 18: MR P.H. (Date of birth 0711011921) 
January 1981 Rapidly progressive pyoderma gangrenosum of anterior thighs over 
two week period. Routine full blood count- Acute myeloid leu-
kaemia. (Confirmed on bone-marrow aspiration). Treatment: CHE-
MOTHERAPY (cytosine I VP16 I Adriamycin) + FULL 
ANTIBIOTIC COVER. Course: Rapidly downhill. Died 
19102!1981. (Cause of death : acute renal failure secondary to uncon-
trolled haemorrhage due to the leukaemic state). In the 3 weeks fol-
lowing diagnosis of PG and leukaemia, the PG lesions had continued 
to enlarge alarmingly. 
COMMENT As previously noted, rapidly progre36ive PG lesions in leukaemic states are 
usually indicative of severe disease . This patient did not have the bullous var-
iety of PG described in association with leukaemia, instead the lesions started 
as deep-seated dermal nodules which rapidly broke down to form the charac-
teristic clinical lesions of PG. Although no record exists of the lesions having 
been biopsied or cultured (except for a pus swab from which a scanty growth 
of acinetobacter was cultured), a confident clinical diagnosis of PG was made. 
CASE 19 : MR W.J. (Date of birth 03/06/1918) 
September 1985 
May 1986 
April 1987 
June 1987 
August 1987 
Myelodysplasia diagnosed (presented with refractory anaemia in 
June, 1983). 
Erosive vegetative lesion of right groin (bacterial, fungal, viral cul-
tures negative, histology- non-specific chronic inflammation). Treat-
ment : Antibiotics, topical antiseptics. Course : Slowly progressive, 
no healing. Myelodysplasia active. Treatment : Blood transfusions. 
Typical PG of left thigh. Treatment: Prednisone 40mg/daily. Course 
: Both thigh and right groin lesion healed promptly. (Right groin le-
sion now considered to be"atypical" PG). Myelodysplasia active. 
Treatment : Intermittent blood transfusions. 
Skin lesions completely healed. Weaned off corticosteroids. 
Cough, fever, acutely ill. Blast crisis. Rapid deterioration. No evi-
dence of PG. Died 5 days after admission. Post-mortem: Pulmonary 
mucormycosis. Acute renal failure. 
COMMENT 
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PG healed rapidly on corticosteroids at a time when his haematological dis-
ease was at a low level of activity. It did not recur when the underlying myelo-
dysplasia transformed to a frankly leukaemic state associated with 
mucormycosis. This patient presented with the slowly progressive form of PG, 
despite having active underlying disease. 
CASE 20: MRS M.S. (Date of birth 08/09/1915) 
1974 Myeloproliferative syndrome. 
1977 Treatment : Splenectomy. Hydroxyurea 1500mgldaily. 
January 1987 Bullous pyoderma gangrenosum near right lateral malleolus (figure 
8). Rapidly progressive. Myelofibrosis stable. Treatment : Predni-
sone 60mgldaily for a week. Course: Continued to enlarge. Treat-
ment : Pulse Methylprednisolone 1G !VI/daily x 3 days then oral 
prednisone 60mgldaily. Course: Immediate reduction in pain. Grad-
ually healed over 4 weeks. Prednisone tapered over next 8 weeks. 
March 1987 Off prednisone. PG healed. 
March 1989 Died following rapid deterioration in haematological disease. 
COMMENT Single episode of "atypical bullous PG" with favourable response to pulse ther-
apy. Pulse therapy is indicated, as in this case, when lesion is rapidly enlarging 
despite an adequate oral dose of prednisone ( 1 mg!kg!day ). This patient de-
veloped PG when her haematological disease was relatively stable, and there 
was no PG recurrence when it deteriorated. Most authors of reports of PG as-
sociated with myelofibrosis, myelodysplasia and leukaemia are of the opinion 
that PG usually acco11:1gq,qies or predicts an acute relapse (days or weeks) of 
the underlying disease - . 
CASE 21: MR P.S. (Date of birth 08/07/1918) 
1984 MYELODYSPLASTIC SYNDROME. Treatment : Intermittent 
blood transfusions. 
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January 1987 Pyoderma gangrenosum diagnosed (non-healing ulcer of right upper 
thigh for 2 years) (figure 15). Myelodysplasia "stable". Treatment: · 
Prednisone 40mg/daily. Clofazamine 300mg/daily (added 4 weeks 
later when prednisone alone had no effect). 
March 1987 Clofazamine stopped. Lesion static at 7cm x 6cm. Maintained on 
prednisone 15mg/daily. 
April 1987 No change. Methotrexate Smg/weekly Prednisone 15mg/daily conti-
nued. 
November 1987 Methotrexate stopped. Sulfasalazine 4G/daily substituted. 
February 1988 Fractured right femur. 
July 1988 DIED. (Associated disease deteriorated acutely). PG remained un-
changed from time of presentation. Was still on prednisone 
15mg/daily and sulfasalazine 4G/daily at time of death. 
COMMENT From the time that a diagnosis of PG was first made in 1987, the lesion re-
mained completely static, neither advancing nor healing. Patient's major com-
plaint was deepseated pain at the site. Repeated biopsies (including deep 
sections) failed to reveal anything but chronic inflammatory cells. Cultures for 
bacteria, deep fungi, tuberculosis and atypical mycobacteria were repeatedly 
negative. This patient may have benefited from pulse methylprednisolone ther-
apy or perhaps higher doses of oral corticosteroids. 
CASE22: 
(THIS PATIENT IS A SUBJECT OF A PREVIOUSLY PUBLISHED REPORT)29 
1984 
1986 
Large necrotic ulcer of right leg. Fever. Hb 6. Full blood count and 
bone-marrow aspirate - ACUTE MYELOID LEUKAEMIA. Ulcer -
PYODERMA GANGRENOSUM. Treatment: Cytosine arabino-
side, doxorubicin, VP 16 - 213. Course : Complete remission (leu-
kaemia). Skin lesions healed completely over 8 weeks. 
Relapsed (leukaemia). PG recurred at same site. Treatment: Fur-
ther chemotherapy (unsuccessful). Course: Died from overwhelm-
ing sepsis. · 
COMMENT 
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Treatment of underlying disorder resulted in resolution of PG (the first time) 
but with recurrent disease, (associated with recurrence of PG) the same result 
was not achieved. The favourable response first time round, was probably re-
lated to the effect of the therapeutic agents on the underlying disease, rather 
than a direct effect on the ulcer. The severity of the leukaemia on the second 
occasion probably accounted for non-healing of PG, despite intensive che-
motherapy. 
CASE 23: MR M.B. (Date of birth 18/07/1898) 
November 1971 Anaemia, loss of weight, ulcers of right leg x 2 months. Diagnosis: 
Acute myeloblastic leukaemia. Non-specific leg ulcers. Treatment: 
"Conservative". · 
January 1972 New ulcers developed on right thigh. Patient acutely ill. Diagnosis : 
Pyoderma gangrenosurn. Treatment: Conservative for skin lesions. 
For leukaemia- "mild course of cytosine followed by thioguanine" 
suggested by haematologists (but no record of this having been given 
was available). Course: Unknown. No further follow-up in hospital 
folder. Last record as above. 
COMMENTS This patient had slowly progressive lesions of PG despite the underlying 
haematological disease. 
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CHRONIC ACTIVE HEPATITIS (CAH) 
CASE 24: MISS A.V. (Date of birth 10/08/1971) 
1984 
June 1989 
June 1990 
13 years old. CAH diagnosed. Treatment: Prednisone lOmg/alter-
nate days. Azathioprine lOOmg/daily. 
Pyoderma gangrenosum (started off as numerous vesicopustules of 
buttocks, elbows, wrists and backs of thighs, progressing to more typi-
callesions of pyoderma gangrenosum and healing with cribriform 
scars). Treatment: Prednisone increased to 20mg/daily. (Azathio-
prine lOOmg/daily) CAH considered in remission. 
Intermittent relapses and remissions of PG. Treatment : Prednisone 
increased intermittently to 40mg/daily. Deterioration of skin lesions 
usually related to deterioration of hepatitis, but this is not a constant 
feature. 
September 1990 Skin and liver disease in remission on prednisone 20mg/daily and 
Azathioprine lOOmg/daily. 
COMMENT As previously rep01ted91, the activity of the hepatitis does not necessarily paral-
lel the activity of the skin lesions. This young woman's liver disease had pro-
gressed to such a degree that liver transplantation was being considered. When 
she first developed lesions, they were crops of small vesica-pustules and a diag-
nosis of first, papulonecrotic tuberculid and later hepato-cutaneous syndrome 
was considered. Chronic inflammatory histology, non-reactive mantoux, exten-
sion of lesions to more florid purplish lesions that healed in parts with cribri-
form scarring while the active edge advanced (even though it lacked 
undennining), suggested a diagnosis ofpyodelma gangrenosum. 
CASE 25: MR A.B. (Date of birth 10/10/1947) 
1969 
1973- 1976 
22 years old. CAB. Treatment : Prednisone. 
Extensive superficial ulceration of arms, legs and trunk. Diagnosis : 
"Recurrent impetigo". Treatment: Antibiotics (repeated). Response-
healed with extensive cribriform scars. Every relapse of skin ulcera-
tion associated with flare of liver disease. Treatment : Prednisone 
(for liver) but skin healed as well. 
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August 1976 Referred dermatologists. New ulcers on hands and legs. Diagnosis: 
Pyoderma gangrenosum. Treatment: Prednisone 40mgldaily. Re-
sponse - PG healed. 
December 1976 Off all treatment for two months (poor compliance). Marked liver 
decompensation and renal failure. DIED. No recorded PG at time of 
death. 
COMMENT This patient had slowly progressive lesions of PG associated with CAH. The 
skin lesions were arrested by prednisone therapy, but recurred when treatment 
was stopped. Recognition of the skin lesions as PG led to more consistent ther-
apy with prednisone. At the time of death, no mention is made of whether ac-
tive skin lesions were present. 
CASE 26: MISS F.B. (Date of birth 15/03/1974) 
November 83 Post-streptococcal acute glomerulonephritis (AGN). Chronic active 
hepatitis (CAB). Chronic, recurrent impetigo (mainly legs). 
February 1984 Prednisone and Azathioprine commenced for CAH. AGN resolved. 
Nov '84- Nov '86 Recurrent necrotic leg ulcers associated with deterioration in CAH. 
Healed with increases in prednisone dosages, only to relapse with re-
duction of prednisone below 20mgldaily. Also recurrent hoarseness 
for which no cause was found. Treatment :. Prednisone 20mgldaily. 
Azathioprine 50mgldaily. (Patient was not compliant with treatment). 
November 1986 Leg ulcers diagnosed as pyoderma gangrenosum by the dermatolog-
ists. Treatment : Prednisone 30mgldaily. (Azathioprine had been 
stopped). 
Nov 1986- Jan 1990 Chronic relapsing course of PG and CAB despite prednisone. 
Feb 1990- Jul1990 Nephritis recurred. Ulcers problematic. Hoarseness persisted. CAH 
troublesome. Treatment: Prednisone 15mgldaily. 
August 1990 Severe oral ulceration, including destructive lesions of the tongue 
and vocal cords. (Biopsies - Chronic inflammation). Ongoing leg ul-
cers, deterioration in liver and renal functions. Treatment : Predni-
sone 30mgldaily, Azathioprine 50mgldaily, Colchicine 1G/daily. 
October 1990 Marked improvement in general condition with near complete heal-
ing of leg and oral ulcers had taken place. Voice had begun to return 
to normal. 
COMMENT This young woman had required numerous admissions for both medical and 
dermatological problems since the age of 8 years. Lack of compliance earlier 
in her course may account for the progressive deterioration of underlying sys-
temic disorder, as well as oral and cutaneous ulcerati~g_3'lhre oral lesions may well have been PG. Oral PG has been rarely repmted - . These patients re-
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sponded to high dose corticosteroid therapy. Kennedy et az36 recommend that 
for laryngeal lesions, fiberoptic nasopharyngoscopy or direct microlaryngos-
copy, for better inspection, be employed. 
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TAKAYASU'S ARTERITIS 
CASE 27: MISS A.L. (Date of birth 23/12/1966) 
August 1982 
March 1984 
May 1984 
September 1984 
· February 1987 
June 1987 
November 1987 
December 1987 
August 1988 
Thrombophlebitis. Iron-deficiency anaemia. Thrombocytosis. Treat-
ment: Iron supplements. Bedrest. Improved spontaneously. 
Extensive pyoderma gangrenosum (started on legs, subsequently in-
volved trunk, upper limbs and face). Absent brachial, radial pulses. 
Bruits over femoral arteries. ANGIOGRAPHY -TAKA YASU'S 
ARTERITIS. Treatment: (for skin) Prednisone 60mgldaily. 
PG healed. Prednisone tapered. 
Acute deterioration of PG on Prednisone 5mgldaily. Stormy course. 
Rapidly progressive PG. Treatment: Prednisone increased to 
150mg!daily plus the following adjuvants in sequence :- clofazamine, 
cyclophosphamide, doxycycline, INH, monocycline, colchicine, etreti-
nate, dapsone, cyclosporin, anti-tuberculous therapy, (INH, rifam-
picin, ethambutol), azathioprine. On occasion, the addition of a new 
adjuvant would appear to halt the progression, but any attempt to re-
duce oral prednisone to below 60mg!daily would result in such a 
rapid deterioration, that the dose of prednisone would then have to 
be doubled to achieve control. Each adjuvant was tried for periods of 
4 to 6 weeks before abandoning as ineffectual or for unacceptable 
side effects. 
Sulfasalazine 4G/daily tried. Positive response apparent. Prednisone 
tapered cautiously from 120mg!daily. 
Treatment: Prednisone 80mgldaily. Sulfasalazine 4G/daily. For the 
first time in two and a half years the PG lesions healed sufficiently 
for her to be discharged home "permanently". (During the two and a 
half year hospital stay, she was allowed home on weekends as often 
as possible, but this was always extremely difficult in view of the ex-
tensive dressings she required). 
Treatment: Prednisone 55mg!daily. Sulfasalazine 4G/daily. Exten-
sive cribriform scarring but only 3 small active lesions of PG on one 
thigh. 
Moderate deterioration in PG. Treatment: Prednisone 150mgldaily. 
Clofazamine 300mgldaily substituted for sulfasalazine. Response : 
Healed slowly. Prednisone tapered. 
Four small active PG ulcers on legs. Treatment: Prednisone 
55mgldaily. Clofazamine 200mgldaily. Developed clofazamine in-
duced "bronze pigmentation". 
September 1988 
September 1990 
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Course complicated by cutaneous and cerebral nocardiosis (from pul-
monary source). Treatment : IVI Amikacin x 10 days. Co-trimoxa-
zole 4 b.d. x 1 year then 1 b.d. indefinitely. Response : All lesions of 
nocardiosis resolved. Recovered completely. Remaining skin lesions 
of PG healed as well. 
Stable. Prednisone tapered to lOmgldaily. Clofazamine stopped in 
·March 1990. On maintenance Co-trimoxazole 1 b.d. 
COMMENT Despite a protracted, stormy course, this young woman entered a phase of re-
mission. (Despite a life-threatening complication of the prolonged cortico-ste-
roid therapy, i.e. disseminated nocardiosis). The response of her skin ulcers 
appeared to be dependent on the dose of corticosteroid and the value of the 
several different "adjuvants" must be seriously questioned. This patient illus-
trates the therapeutic dilemmas of the attending physician when confronted 
with a patient with such extensive disease: 
1. Side effects of high dose, long-term corticosteroid therapy. 
2. Narcotic dependency (these patients often require frequent administration of narcotic an-
algesia to control the accompanying pain). 
On review, this patient might have benefited from pulse methylpred-
nisolone therapy, earlier in her course. 
The Takayasu's arteritis had progressed slowly over the years, mani-
festing as moderate hypertension, mild impaired renal function and 
mild cardiomegaly. The majofMy of patients with Takayasu's and PG 
have been described in Japan . The clinical picture in the reported 
cases (twenty-six in the Japanese literature) is identical to those 
where PG is associated with diseases other than Takayasu's arteritis. 
The relatively high association of Takayasu's arteritis and PG in the 
Japanese population remains unexplained. 
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ENDOMETRIOSIS 
CASE 28: MRS S.P. (Date of birth 03/08/1931) 
November 1975 Total abdominal hysterectomy and left salpingo-oophorectomy. (en-
dometriod cyst of left ovary present). 
April 1976 Vesico-vaginal fistula (edges of which showed histological evidence 
of endometriosis). Repair attempted, but edges of wound failed to 
heal. 
July 1976 New lesions developed in addition to the perineal ulceration. Large 
painful ulcers developed on back and anterior abdominal wall which 
gradually healed on no specific therapy over 18 months. 
February 1978 Vesico-vaginal fistula broke down for the third time. In addition, ex-
tensive lesions of pyoderma gangrenosum of abdomen, buttocks, legs 
and one ear developed. Treatment : Methylprednisolone 64mg/daily. 
Clofazamine 300mg/daily. Vaginal cavity surgically obliterated. 
Course: Patient achieved partial urinary continence. Pyoderma gan-
grenosum healed completely after 3 months in hospital. Discharged 
on maintenance dose of Methylprednisolone 16mg/daily and clofa-
zamine 300mg/daily. Failed to return for follow-up and it has been 
established that patient died 1 year later after yet another attempt to 
correct her urinary incontinence. (Cause of death was given as post-
operative "septic shock.") She apparently did not have recurrence of 
pyoderma gangrenosum following her discharge from Groote Schuur 
hospital. 
COMMENT This patient is a §lfhject of a case report that appeared in the South African 
Medical .Journal . The vulval as well as cutaneous lesions responded to ade-
quate doses of corticosteroids and clofazamine. The role which endometriosis 
played in the pathogenesis of PG and the vesico-vaginal fistula in this patient, 
remains speculative. P.<;ychological support and counselling in patients with e43 
tensive perineal involvement should form an important part of management . 
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BEHCET'S SYNDROME 
CASE 29 : MR N.B. (Date of birth 19/01/1955) 
June 1975 
December 1975 
April1976 
Diagnosis : Behcet's syndrome (Recurrent oral and genital ulcers, 
sterile pustules, sacro-ileitis ). Treatment : Fibrinolytic therapy. 
(phenformin + ethylestranol). Course: No improvement. 
Pyoderma gangrenosum developed over both lower legs. Treatment : 
Prednisone 40mg/daily. Clofazamine 300mg/daily. Dapsone 
100mg/daily. (The latter added to the former two, when after six 
weeks, complete control of skin lesions had not been achieved). 
Course : AJl skin lesions (including oral and genital ulcers and pus-
tules healed completely over the next 3 months). 
Polyarthritis. Treatment : Non-steroidal anti-inflammatory drugs. 
Maintenance: Prednisone lOmg/daily. Clofazamine 200mg/daily. 
Dapsone 100mg/daily. 
April 1976- Feb 1981 Followed up in Transkei. Repeated episodes of pyoderma gangreno-
sum when stopped taking medication but with prompt healing on re-
institution. Resulted in extensive cribriform scarring of arms and legs. 
February 1981 Sacro-ileitis. Uveitis. Treatment: Bed rest. Prednisone lOmg/daily. 
Clofazamine 200mg/daily. Dapsone 100mg/daily. 
Feb 1981- June 1986 Stable. Stopped taking medication from June 1986. 
July 1986 Deterioration. Attended a different hospital. Medication only rein-
troduced in December 1986. By then had developed extensive le-
sions of PG on lower legs and upper limbs. Treatment: Prednisone 
lOmg/daily, clofazamine 300mg/daily, dapsone lOOmg/daily. 
February 1987 Referred back to GSH for re-evaluation. At that stage, he had 1/2cm 
x 1/2cm lesion of PG on right shin. All treatment stopped at GSH. 
Within one week of stopping medication, he deteriorated slowly, 
with development of apthous oral ulcers, sterile pustules, enlarging 
of old and development of new PG lesions on the legs. Treatment : 
Prednisone 20mg/daily. Reponse : Healed completely within two 
weeks. , 
March 1987 Discharged back to Transkei on maintenance prednisone lOmg/alter-
nate days. No further follow-up available. 
COMMENT Pyoderma gan!f!6mosum has previously been reported in association with Beh-
cet's syndrome . The two conditions share some features: pustules and folli-
culitis, pathergy, non-spec~fic histological appearances, a range of agents used 
to treat either condition demonstrate a similar overlap. (Corticosteroids are 
the mainstay of treatment in both disorders). The above patient demonstrated 
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a surprisingly good response to relatively low starting (20mg/daily) and main-
tenance (lOmg!alternate days) doses of prednisone. His response on the sec-
ond occasion indicates that dapsone and clofazamine probably contributed 
very little, if anything, to the clinical response on the first occasion. 
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LEUCOCYTOCLASTIC VASCULITIS 
CASE30: MISS M.M. (Date ofbirth 03/10/1971) 
January 1988 
July 1989 
May 1990 
June 1990 
July 1990 
August 1990 
September 1990 
October 1990 
Fever, mass loss, polyarthralgia, Raynaud's phenomenon, necrotic ul-
cers of left elbow, right ankle. Investigations : Haematology - an-
aemia of chronic disorders. ESR 63. Chest X-ray, ECG, 
biochemistry, VDRL, streptococcal serology, cryoglobulins, protein 
electrophoresis, circultating immune complexes, c-reactive protein, 
echo-cardiogram, collagen screen, rheumatoid factor, ANF were all 
negative or normal. Histology of edge of ulcer - non-specific chronic 
inflammation. Diagnosis : "Probable collagen vascular disease. 
"Treatment : Bedrest. Spontaneously improved. 
On-going joint pain. Vesica-pustules over proximal interphalangeal 
joints, knees, around ankles. Small vasculitic infarcts around left 
thumbnail. Bacterial endocarditis excluded. Histology : Prominent 
neutrophilic infiltrate in dermis. No vasculitis. Diagnosis : Early vesi-
ca pustules of pyoderma gangrenosum. (Barium studies negative). 
Treatment : Prednisone 60mg/daily. Dapsone lOOmg/daily. Course : 
Skin lesions and arthralgias resolved·over the following 3 months. 
Weaned off corticosteroids. Generally so well that Dapsone stopped 
as well. 
Polyarthralgia recurred. Treatment : Non-steroidal anti-inflamma-
tory drugs. Response : Good. 
Acute, rapidly progressive lesions of more typical pyoderma gan-
grenosum developed (figure 21). Treatment: Minocycline 
200mg/daily lWrr~ on favourable response of PG responding to this 
agent alone) ' . Course : PG lesions healed favourably. 
While PG lesions were healing, she developed a shower of acrally 
distributed haemorrhage papules, histology of which revealed LEU-
COCYTOCLASTIC VASCULITIS. For the first time she also de-
veloped microscopic haematuria. Diagnosis : Systemic 
leucocytoclastic vasculitis. Renal biopsy : Focal necrotising glomeru-
lonephritis. Minocycline stopped. Treatment : Prednisone 
60mg/daily. Pulse cyclophosphamide. 
All skin lesions healed but developed pneumococcal pneumonia. 
Treatment : Antibiotics Course : Resolution. Oral prednisone and cy-
clophosphamide continued. 
Renal and cutaneous lesions stable on therapy. Diagnosis: "Vas-
culitic syndrome - Probably systemic lupus erythematosus (SLE)" 
Plan: Continued maintenance prednisone and cyclophosphamide 
and await developments. 
COMMENT 
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This patient presented with a systemic illness from the onset (fever, 
mass loss, anaemia, polyarthralgia) in addition to her skin lesions. An 
aggressive therapeutic approach was adopted with the development 
of glomerulonephritis, in order to prevent further renal detenora-
tion. This patient clearly had a systemic vasculitic syndrome which, al-
though not clearly defined, was expected to evolve into SLE. The 
occurrence of leucocytoclastic vasculitis and pyoder~.5iflngrenosum 
in the same patient has been previously documented ' , but in 
these patients the PG developed several years after cutaneous vas-
culitis was demonstrated. 
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lgA GAMMOPATHY 
CASE 31: MR N.M. (Date of birth 29/11/1926) 
August 1990 
September 1990 
COMMENT 
Rapidly enlarging ulcer of right buttock. Started spontaneously. Diag-
nosis : ? Atypical infection. Investigations : negative. Treatment : Sur-
gical debridement. Antibiotics. Course : Continued to enlarge 
alarmingly. 
Referred dermatologists. Diagnosis : Pyoderma gangrenosum. Inves-
tigations : All negative except lgA gammopathy. Treatment : Pulse 
therapy (1G methylprednisolone lVI daily x 3) followed by predni-
sone 60mg/daily. Course: Completely healed in two weeks. On main-
tenance oral prednisone. (Starting dose 60mg/daily with cautious 
tapering planned). 
Previously well patient with sudden onset of acutely progressive PG 
that responded promptly to pulse therapy. He is the only patient in 
the GSH series with a documented IgA gammopathy (urine for 
Bence-Jones protein was negative). The gammopathy was con-
sidered to be of undetermined significance. This patient should prob-
ably have an annual screen for myeloma. 
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IDIOPATHIC PYODERMA GANGRENOSUM 
CASE 32 : MR W.L. (Date of birth 02/02/1908) 
April1971 
August 1971 
October 1971 
COMMENT 
Bullous Pyoderma gangrenosum. (Multiple, haemorrhagic bullae of 
both legs and right wrist that progressed to more typical lesions of 
pyoderma gangrenosum). No associated disease found. (In particu:.. 
lar, no haematological disorder). Treatment: Methylprednisolone 
32mg/daily. Course: "Almost" healed by July, 1971. 
Acute deterioration of existing pyoderma gangrenosum and develop-
ment of new lesions (associated with a deep vein thrombosis, an-
aemia and haematoma of left kidney). Diagnosis:? Malignancy. · 
(None found). Treatment: Prednisone 80mg/daily. Course: Pro-
gressive deterioration. 
DIED. Cause. of death: unknown. (Post-mortem refused). 
Despite numerous investigations, (including laparotomy to exclude 
lymphoma, renal carcinoma) no cause could be established for this 
patient's eventual demise. A bone marrow investigation was sug-
gested but no record of this having been done exists in the patient's . 
notes. (A full blood count, coagulation studies, protein electro-
phoresis were normal). This man's rapidly progressive deterioration 
was suggestive of "a malignancy somewhere" but none was found. A 
bone-marrow investigation may well have given the answer, particu-
larly in view of the bullous nature of the PG lesions. 
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IDIOPATHIC PG 
CASE 33: MR P.O. (Date of birth 22/03/1947) 
1963 Right groin swelling following rugby injury. At laparotomy, ileoas-
cending colectomy performed for presumed Crohn's but this was not 
confirmed histologically. Post-operatively required (over the next 14 
months), four abdominal operations for poor wound healing, wound 
dehiscence and abdominal dehiscence. After the fourth operation, 
all wounds gradually healed. 
December 1964 "Cysts" excised from above right eyebrow and right cheek. Healed 
with no problems, but a few months later, right cheek scar became 
swollen and within a few days softened and discharged pus. Rapidly 
increased to a Scm ulcer with an undermined edge. 
Dec 1964- Dec 1966 Non-healing ulcer right cheek. Histology non-specific. Cultures (bac-
terial, fungal, viral)- negative. Treatment :Remained virtually static 
at Scm size. 
January 1967 Cluster of pustules developed on LEFf cheek. Rapidly progressed 
to approximately Scm ulcer with undermined edges. Diagnosis : non-
specific ulcer (histology and cultures unhelpful). 
April 1968 Developed ulcer of right knee. Diagnosis : ? dermatitis artefacta. 
Treatment : Antibiotics I topical ointments. Course : Knee ulcer 
healed over a period of a year. Cheek ulcers persisted. 
June 1970 Attended private dermatologist for persistent bilateral cheek ulcers. 
Diagnosis : Pyoderma gangrenosum. Treatment : Oral prednisone. 
Course : Rapid and complete healing of both lesions over a period of 
16 weeks. 
September 1972 Stable on maintenance prednisone. 
October 1972 Went overseas. Stopped taking prednisone. 
May 1973 Referred to GSH with extensive ulceration of both cheeks and bilat-
eral ectropions. Treatment: Medrol 64mg/daily. Tetracycline 1G 
daily. Bilateral Wolfe grafts for ectropions once adequate healing 
had taken place. Course : Acceptable cosmetic result with ectropion 
repairs. Right cheek ulceration healed completely over a period of 
30 weeks. Small area of persistent ulceration on left cheek. 
September 1973 LEFT ECTROPION recurred. 
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Oct 1973 - Oct 1974 Had a total of NINE plastic surgical procedures over this period to 
try to correct left recurring ectropion. Treatment : Methylpredniso-
lone 20- 40mg/daily. Tetracycline 500mg/daily. Course : Any attempt 
to reduce Medrol to below 20mg/daily resulted in breakdown. Vi-
cious cycle established : breakdown - healing - ectropion - surgery -
breakdown etc. 
Oct 1980- Aug 1981 "Grumbling" pustulation of left cheek (figure 6). Treatment: Methyl-
prednisolone 28mwdaily. Course: Complicated by development of 
severe osteoporosis, proximal myopathy, cushingoid features. He did 
not develop diabetes mellitus. Fractured both achilles tendons and 
metatarsal in right foot during this period. 
Aug 1981- Mar 1983 Transferred to Johannesburg. Weaned himself off corticosteroids. 
Left cheek PG healed. Ectropion recurred. 
March 1983- Dec 198J:I. further surgical procedures attempted to correct left ectropion. 
(Covered with corticostero.ids during and after surgical procedures). 
Course: Initially good effect, but breakdown occurred 4 weeks after 
surgery. During one of these procedures, a lipoma was excised from 
right wrist and this resulted in a large PG ulcer developing in that 
area; this eventually healed on high-dose Methylprednisolone, 
64mg/daily. 
Dec 1983 - Feb 1989 Treatment : Continuous Methylprednisolone (doses varied between 
20 and 64 mg/daily). In addition, various adjuvants (tetracycline, mi-
nocycline, colchicine, erythromycin clofazamine and dapsone) were 
tried with minimal success as left cheek pustulation persisted and 
continued to deteriorate with reduction of Methylprednisolone 
below 20 mg/daily. 
February 1989 Azathioprine lOOmg/daily added. 
August 1990 18 months of Azathioprine failed to reduce Methylprednisolone re-
quirements below 20mg/daily. 
September 1990 Admitted for pulse Methylprednisolone lG IVI/daily x 3 days. Pustu-
lation completely resolved. A small fibrous papule just below left 
eyelid was shaved at patient's request (with the steroid cover, this ap-
peared to be an appropriate time for this minor surgical procedure). 
Discharged on Methylprednisolone 16 mg/daily. Sulfasalazine 
4G/daily. 
October 1990 Pustulation and tiny areas of erosion recurred at and around site of 
shaved fibroma. Treatment: Methylprednisolone 16 mg/daily. Sulfa-
salazine 4G/daily continued, with the hope that the process will 
eventually settle. 
November 1990 Sulfasalazine stopped (headache). Skin lesions unchanged. Patient 
"fed-up". Planned to wean himself off steroid and seek help from 
homeopath. 
COMMENT This case highlights the delay in diagnosis that often occurs in PG 
(even in the hands of dermatologists). PG can easily be mistaken for 
dermatitis artefacta, as in this man's case, where the PG is appears to 
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be related to trauma. Although PG was only diagnosed in 1970, his 
history suggests that the poorly healing post-operative wounds of 
1963 were probably ulcers of PG. It is interesting that the most active 
site for many years was an area on his left cheek which he constantly 
"picked" at. It would appear that high dose corticosteroid, in this 
case, failed to control the pathergic response. It remains to be seen if 
lesions remain limited, off corticosteroid treatment. 
CASE 34 : MR D.F. (Date of birth 26/09/1978) 
July 1986 
January 1987 
October 1990 
COMMENT 
Pyoderma gangrenosum of head and neck (figure 7). (Slowly pro-
gressive ulcerative process of scalp and face over 1 year). Child 
healthy. No associated disease found. (Barium studies not done). His-
tology : vasculitis. Treatment : Prednisone 40mg/daily. Dapsone 
40mg/daily. Bilateral split skin grafts performed (once adequate heal-
ing had taken place). Course : Slow but favourable healing over 20 
weeks. 
Discharged. PG stable on Prednisone 15mg/daily and Dapsone 
40mg/daily. Course: Failed to come for follow-up. (Lived in a small 
farming community). 
Established that child is completely well and healthy and has had no 
further recurrence of PG. 
Atypical PG of head and neck in a child. The favourable response to 
relatively short courses of oral corticosteroids, dapsone and skin 
grafting was unexpected. No recurrence despite "abrupt" cessation of 
therapy. Of note in this patient was the presence of a necrotising vas-
culitis of the vessels in the mid-dermis (no evidence was found else-
where despite extensive screening). 
CASE 35 : MRS R.J. (Date of birth 30/03/1961) 
June 1989 
March 1990 
Pyoderma gangrenosum developed at site of excised benign breast 
lump. Followed by development of PG lesions on left deltoid, right 
deltoid and right hip. No associated disease found. Healthy. (Barium 
studies not done). Treatment: Methylprednisolone 32mg/daily. 
Course : Healed over 8 weeks. Patient unhappy with weight gain. 
Stopped taking corticosteroid. 
Returned with acute recurrence of old lesions and development of 
new ones on left temple, left malar area and back. 18 weeks preg-
nant. Healthy. Treatment: Methylprednisolone 24mg/daily. Course: 
August 1990 
September 1990 
October 1990 
November 1990 
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Healed over 12 weeks. Remained stable on tapering dose of Methyl-
prednisolone. 
Delivered a healthy infant. 
Off corticosteroid for 8 weeks. Pyoderma gangrenosum of the left 
breast and left arm recurred. Also bloody nasal discharge. Treatment 
:Methylprednisolone 24 mg/daily. 
Skin lesions were almost healed. Bloody nasal di~charge persisted. 
Loss of hearing, right ear. Chest X-ray: bilateral infiltrates. ? Pul-
monary tuberculosis (no acid fast bacilli). ? Vasculitis. 
Referred to otolaryngologic and respiratory departments. Prelimi-
nary investigations: Negative for Wegener's granulomatosis, malig-
nancy, atypical infections. Plan: Further nasal and open lung biopsies 
for diagnostic purposes. No definitive treatment. Continued on main-
tenance methylprednisolone 8mg/daily for PG. Skin lesions com-
pletely healed. 
This patient with skin lesions of PG, bloody nasal discharge and pul-
monary infiltrates may well turn out to be a case of PG with nasal 
and lung involvement (particularly .in the light of the finding of 
chronic inflammatory cells only on histology and negative bacterial 
and fungal cultures on preliminary investigations). 
CASE 36: MR P.E. (Date of birth 31/05!1947) 
April1974 
April1976 
May 1979 
August 1980 
January 1981 
Diagnosis: Pyoderma gangrenosum of lower leg. (Non-healing ulcer 
for 12 years, following a rugby injury). No associated disease. Histo-
logy -vasculitis. Sigmoidoscopy - normal. Treatment : Dapsone 
100mg/daily. Course : Completely healed over a period of 16 weeks. 
Stopped dapsone September 1974. 
Occurrence of PG (left calf)( spontaneous breakdown). Treatment : 
Dapsone 100mg/daily. Course : Completely healed over a period of 
16 weeks. Dapsone stopped July 1976. 
PG occured at site of trauma (left shin). Treatment: Clofazamine 
200mg/daily x 5 weeks. Course: Was apparently healing on clofa-
zamine. Stayed away. 
Ulcer of May 1979 had progressively deteriorated. Treatment : Dap-
sone 200mg/daily. Course : Healed completely over 8 weeks. 
Stopped Dapsone in December 1980. 
Returned with recurrence of PG (noted as "large areas of ulcera-
tion"). Treatment: Dapsone 200mg/daily (1 week supply prescribed). 
Course: Did not come for follow-up. Patient was last heard from in 
January 1987 when ulcers of January 1981 had eventually healed, 
COMMENT 
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over several months, on no specific therapy and had not recurred up 
until that date. 
A chronic, indolent course of 12 years before a diagnosis of PG was 
made and then a very favourable response to dapsone therapy within 
16 weeks. Interesting to note the poor response to clofazamine when 
this was prescribed on one of his recurrences. The finding of leucocy-
toclastic vasculitis on skin histology, with no evidence of systemic vas-
culitis in an ulcer of such long standing is unusual. 
CASE 37: MR C.B. (Date of Birth 09/10/1916) 
June 1977 
September 1977 
March 1986 
COMMENT 
Injured left shin -ulcerated. Diagnosis : "Gangrenous infarct". Treat-
ment : Surgical debridement and split skin graft. Course : "Sepsis" of 
donor and graft sites. Treatment : Antibiotics/ointments. 
Non-healing ulcers of right shin and donor site (left thigh). Diagnosis 
: Pyoderma gangrenosum. Treatment : Clofazamine 300mg/daily. 
Course: No response after six weeks. Clofazamine stopped. Treat-
ment : Methylprednisolone 48mg/daily. Response : Completely 
healed after 8 weeks. Methylprednisolone slowly tapered and event-
ually stopped in November 1978. 
Last recorded hospital visit. Well. No PG. Further follow-up unavail-
. able. 
Pathergy almost certainly contributed to this patient's development 
of PG. His response to oral corticosteroids was prompt and com-
plete. Tapering of corticosteroids took place extremely cautiously 
and no recurrence of PG occurred. 
CASE 38: MRS M.N. (Date of birth 01/01/1941) 
March 1977 
December 1977 
March 1978 
Presented with extensive pyoderma gangrenosum. (Legs, arms, 
breast, scalp). Treatment: ACTH. Clofazamine. Partial response. As-
sociated disease: None. 
Further deterioration. Referred GSH. Treatment : Methylpredniso-
lone 48mg/daily. Clofazamine 300mg/daily. INH prophylaxis. 
Healed. 
July 1978 
October 1978 
Follow- up 
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Relapsed on Methylprednisolone 12mg/daily. Treatment.: Methyl-
prednisolone increased to 40mg/daily. Clofazamine 300mgldaily con-
tinued. Course : Healed. 
Discharged back to country hospital on tapering doses of corticoste-
roid and maintenance dose of Clofazamine lOOmgldaily. 
Established that patient died several months after discharge but 
exact nature of Circumstances surrounding her death are unknown. 
Good control for extensive disease achieved on therapy, but relapses 
with reduction of corticosteroid below 12mg/daily. Patient carne 
from rural district, and follow-up was unfortunately not always satis-
factory. An associated disease, despite in depth investigation, was 
never found. 
CASE 39 : MR A.M. (Date of birth 07/05/1968) 
April 1978 Referred with extensive pyoderma gangrenosum that had started in 
the genital area. No associated disorder was found (despite extensive 
investigations, which included bowel studies). Treatment: Predni-
sone 40mg/daily. 
May 1978- Dec 1978 Rampant disease. Clofazamine, dapsone, sulfapyridine, minocycline, 
azathioprine were added in sequence for periods varying between 4 
and 6 weeks, for both therapeutic and steroid sparing effects, but all 
were uniformly unsuccessful. 
27 December 1978 Patient died suddenly during dressing change. (Thought to be due to 
a cardiac arrest following on vasovagal stimulation during dressing 
changes). 
COMMENT Severe, extensive disease, which failed to respond to high dose corti-
costeroid. ( 40mg/daily in a 25kg boy). This is the only case of PG in 
the GSH series where oral corticosteroids in adequate doses failed 
to elicit a positive response. Despite fulminant extensive skin lesions 
(almost total body involvement at the end), no underlying systemic 
disease was found. Judging from the literature review, this degree of 
cutaneous involvement in PG is rare. 
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CASE 40 : MR M.B. (Date of birth 08/09/1954) 
June 1988 
December 1988 
February 1989 
April1990 
July 1990 
September 1990 
COMMENT 
Single superficial lesion of pyoderma gangrenosum of mid back. 
(figure 6). Treatment : Prednisone 40mg/daily. 
Completely healed on tapering doses of prednisone. 
Weaned off prednisone. 
Pyoderma gangrenosum at lower end of previous lesion had re-
curred. Treated himself at home. No improvement. 
Treatment : Minocycline 200mg/daily commenced. Course : Pro-
gressive deterioration. 
Admitted for pulse Methylprednisolone 1 G I VI/daily for 3 days (mi-
nocycline stopped) then continued with oral prednisone 60mg/daily 
and Sulfasalazine 4G/daily. Lesion had begun to decrease in size and 
good healing had taken place when last seen. (15/10/1990). Sulfasala-
zine was stopped as patient complained of intolerable headache . 
. This patient's PG, clinically and histologically, bests fits the superfi-
cial, vegetali.Ye type of pyoderma gangrenosum described by Wilson'"· 
Jones et al. .) 
It remains to be seen whether the aggressive therapy i.e. pulse 
methylprednisolone, results in permanent/prolonged remission. This 
form of therapy was chosen in this patient because of the inac-
cessible site of the lesion for dressings (patient lived alone) and an in-
creasing depression as a result of the constant oozing from the site 
which had adversely affected his working and social life. He may well 
have cleared with consistent therapy (other than corticosi_~roids) had 
the circumstances been ideal. In the Wilson-Jones series , healing 
occurred without systemic corticosteroid therapy in all but three of 
the twenty-five patients~ Healing in the remaining patients took 
place with local or intralesional corticosteroid, minocycline, tetracy-
cline or sulfa drugs. 
CASE 41: MISS M.A. (Date of birth 04/06/1958) 
December 1975 
March 1977 
Three year history of recurrent leg ulcers. Pyoderma gangrenosum di-
agnosed. No associated disorder found. Treatment: Methylpredniso-
lone 24mg/daily. Course: Healed slowly with occassional 
deterioration when failed to take oral corticosteroids. 
Healed completely. 
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April1977 Weaned off corticosteroids. 
April1977- Sep 1990 No further recurrence of pyoderma gangrenosum. Alive and healthy. 
COMMENT This young woman responded to oral corticosteroids alone. The 
maintenance dose of Methylprednisolone for the greater part of the 
course was not more than 8mg/daily and deterioration only occurred 
when she stopped taking the medication altogether. With gradual 
weaning of the corticosteroid (after complete healing had taken 
place) remission has been maintained to date. 
CASE42: MR N.S. (Date of birth 04/08!1928) 
November 1974 
January 1975 
February 1975 
COMMENT 
Ulcer of left lower leg x 4 months (figure 17). Diagnosis : Pyoderma 
gangrenosum. No associated disease. Histology : Leucocytoclastic 
vasculitis. (no systemic involvement). Treatment: Tetracycline 
2G/daily. 
Initial ulcer had healed but new lesion had developed at edge of the 
old lesion. Treatment : Tetracycline 2g/daily continued. Topical care. 
Ulcer "almost healed". Lost to follow-up. 
This is the only patient in the series where tetracycline alone was 
chosen for PG, with apparent initial success. It is interesting that a fa-
vourable response was obtained in a patient where leucocytoclastic 
vasculitis was demonstrated on histology of the cutaneous lesion. 
CASE 43 : MR J .T. (Date of birth 00/00/1905) 
January 1971 
May 1971 
COMMENT 
Admitted with extensive disease involving arms, chest, abdomen. 
Skin ulcers had started 2 years previously. No associated disorder. 
Treatment : Methylprednisolone 64mg/daily. 
Discharged with skin lesions "almost healed". Course complicated by 
development of diabetes me.llitus which gradually resolved as the 
oral corticosteroid was tapered. Follow-up unobtainable. 
Patient spent almost 5 months in hospital with extensive disease. Pa-
tient is known to have remained well after discharge, but unfortu-
nately his hospital record of follow-up visits has been destroyed. 
Extensive investigations revealed no underlying disease. 
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CASE 44 : MR T.P. (Date of birth 00/00/1939) 
September 1981 Referred re non-healing ulcers of legs. Diagnosis: Pyoderma gan-
grenosum. Treatment : Prednisone. Dapsone 100mg/daily. 
1980- Jan 1989 Followed up at country hospital. Episodes of deterioration (mainly 
when he stopped taking the medication). 
February 1989 Admitted to GSH with widespread deterioration. Treatment: Pred-
nisone 80mg/daily. (Subsequently increased to 160mg/daily). 
Feb 1989- Dec 1989 Prolonged hospital stay, due to recalcitrant disease, complicated by 
development of Insulin dependent diabetes mellitus and pulmonary 
tuberculosis. Medications added (in sequence) for therapeutic and 
steroid sparing effects were : Clofazamine, sulfasalazine, azathio-
prine, thalidomide. All of these failed to allow tapering of predni-
sone. Throughout hospital stay, no control of PG was ever attained. 
December 1989 DIED. (Cause of death- DIABETIC KETOACIDOSIS). Still had 
several areas of ulceration. Treatment at time of death : Prednisone 
lOOmg/daily Azathioprine lOOmg/daily, Thalidomide 200mg/daily. 
(The prednisone had been cautiously lowered just prior to his death, 
as the thalidomide which had been started 4 weeks prior to his death 
appeared to be having a positive effect. Unfortunately, he suc-
cumbed to the diabetic state when allowed home for a short period 
after an 11 month continuous hospital stay). 
CASE 45: MR G.T. (Date of birth 06/09/1944) 
August 1977 
November 1977 
February 1978 
"Abscess" of left inguinal region incised and drained. Complained of 
haemoptysis - Mantoux -ulcerated to such a degree that grafting of 
the area was required. Repeated sputa for acid-fast bacilli (AFB) ne-
gative. Treatment : Antibiotics Course : Grafted area healed poorly. 
Ongoing haemoptysis, loss of mass, fever. Skin lesions persisted. Di-
agnosis: Pulmonary Tuberculosis (TB)(postive sputum culture). 
Treatment : Rifampicin, Streptomycin, Isoniazid. Course : Re-
sponded favourably re TB but skin lesions persisted. 
New cutaneous ulcers developed (lower limbs). Treatment: Antibio-
tics. Course : Healed poorly 
September 1978 
January 1979 
Diagnosis : Pyoderma gangrenosum. Treatment : Clofazamine 
300mgldaily. Response: Healed poorly. 
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Further deterioration. Treatment : Methylprednisolone 32mgldaily. 
Isoniazid prophylaxis. Response : Good. 
Feb 1979- Aug 1981 Intermittent flares of PG required increases of methylprednisolone 
from 12mgldaily to 48mgldaily (for short periods). Course: PG 
healed completely by August 1981. 
September 1981 Recurrence of severe pulmonary TB. (despite isoniazid prophylaxis-
although compliance with therapy was questioned). Treatment : Ri-
fampicin, Ethambutol, Isoniazid. Maintenance methylprednisolone 
8mgldaily. 
January 1982 Failed to come for TB and PG follow-up. 
April 1982 Lung disease flared. No PG present. Treatment: Anti- TB treat-
ment re-introduced. Course : General condition deteriorated. 
September 1982 Admitted to TB hospital. Extensive pulmonary disease. 
October 1982 PG started to flare. Despite anti-TB therapy, died on 26/10/1982. 
I 
COMMENT This patient's PG was associated with troublesome pulmonary tuberculosis. 
Tests of neutrophil function, prior to commencing corticosteroid therapy for 
PG, showed a neutrophil killing time of 0% (compared to 100% of the con-
trol). The chemotaxis and phagocytosis was apparently normal. An "ulcera-
ting" mantou.x indicated adequate ceYs'YT(fdiated immunity. Neutrophil defects 
in PG have been reponed in the past - . A !though drug resistance may have 
been a problem at the end, the overwhelming nature of the pulmonary disease 
indicated a breakdown in immune mechanisms (more likely humoral). Al-
though PG was only diagnosed in 1978, the ulcerating Mantoux of 1 year pre-
viously and subsequent poor healing thereajte1~ indicates that it was probably 
an area of PG already at that stage of the disease course. 
